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Opposing functions of activated microglia, namely neuroprotection or neurotrophy versus 
neurodestruction or neurotoxicity, have been observed in a number of experimental 
models of neurotrauma and neurodegenerative diseases. However, the mechanism(s) 
involved in the determination of which function activated microglia execute under a 
given set of conditions still remains to be elucidated. Our current in vitro study has 
revealed that a neuroprotective/neurotrophic or a neurodestructive/neurotoxic microglial 
function may be configured by the equilibrium among various microglial factors released 
into the microenvironment. When NSC-34 neurons were treated with lower 
concentrations of lipopolysaccharide-stimulated BV-2 cell conditioned medium (LPS-
BVCM), viability of the NSC-34 neurons increased, outgrowth of neuronal processes was 
promoted, and the formation of 2,5-hexanedione-induced aggregates was prevented. 
However, when NSC-34 neurons were treated with higher concentrations of the same 
LPS-BVCM, neuronal viability was reduced, apoptosis was induced and outgrowth of 
neuronal processes was suppressed. It is postulated that an alteration in the concentration 
of the LPS-BVCM might significantly affect the functional balance of microglial factors 
in the microenvironment with a resultant different microglial function. 
 
During the study on the microglial dual functions, the expression change of some Bcl-2 
family members have also been observed. One interesting finding is that only Diva’s 




Diva (Death Inducer Binding to vBcl2 and Apaf-1), a newly identified Bcl-2 family 
member, has been reported to be only expressed in ovary but not other tissues in adult 
mouse. At the same time, both anti- and pro-apoptotic functions of Diva have been 
reported by different groups. Furthermore, as one of the Bcl-2 family members, the 
possible involvement of Diva in the regulation of cell cycle has never been investigated.  
 
Our present study  intended to identify the possible role of Diva during the microglia dual 
effects, investigate the distribution of Diva in central nervous system and study the 
possible involvement of Diva in the regulation of cell cycle in neural stem cells in vitro.  
 
By fluorescent double-labelling, we found that Diva translocated from cytosol onto 
mitochondria under the protective effect of microglia. Furthermore, overexpression of 
Diva in NSC-34 cells resulted in an increase of proliferation rate and rescued NSC-34 
neurons from death indicating an anti-apoptotic role of Diva. 
  
By immunohistochemistry, it was shown that Diva is expressed in some nuclei in the 
brain stem of adult mouse. Double labelling of Diva with several cell markers further 
indicates that Diva is only expressed in neurons but not astrocytes, oligodendrocytes, 
microglia or NG-2 cells. This result is different from previous findings in which Diva 
was reported to be only expressed in ovary in adult mouse. 
 
The promotion of proliferation rate by overexpression of Diva in NSC-34 cells suggests 




down-regulation of Diva’s expression after the differentiation of neural stem cell has 
been observed which indicates that Diva could arrest the neural stem cells in the G0/G1 
phase and prevent the escaping of neural stem cells from cell cycle. The pioneer study in 
the project has emphasized on the regulatory function of Diva during the cell cycle in 
neural stem cells.The results plus the anti-apoptotic role of Diva would lead further 
project in the future on microglial dual functions on transplanted stem cells.  
 
In conclusion, our results suggest that Diva is not only expressed in the adult ovary, but 
also in some specific nuclei in the mid-brain and pons and spinal cord of adult mice. In 
vitro studies indicate that Diva played an anti-apoptotic role under microglial 
cytotoxicity. Furthermore, it is interesting that Diva may play an important role during 
the neural stem cell differentiation, which may lead to identification of the new way to 
regulate the fate of multipotent stem cells. The capability of manipulating the 
differentiation of neural stem cells may also be helpful to the stem cell transplantation 
therapeutic strategies to treat neurological diseases and CNS injuries. 
 


























1. Microglia in the central nervous system 
It had been a long time that the central nervous system (CNS) was recognized as 
immunologically privileged because it has a very effective blood brain barrier based 
on the tight junction at the vasculature that prohibits the free access of serum 
components and blood cells to the brain tissue. This indicated that the CNS did not 
have its own intrinsic immune system and this concept had not been questioned until 
the discovery of up-regulated expression of major histocompatability complex (MHC) 
I and II molecules in the population of resident microglia (Matsumoto et al., 
1992a;Vass and Lassmann, 1990). Although microglia had been first described as the 
third element in the CNS by del Rio Hortega in 1932 (del Rio-Hortega, 1932), it had 
not attracted researchers’ great interests until the later 1980s because of microglial 
reactive responses in various pathologies including axonal injury, ischemia, tumors, 
traumatic damage, neurodegenerative diseases, infectious and autoimmune CNS 
diseases (Banati and Graeber, 1994;Gebicke-Haerter et al., 1996;Gehrmann et al., 
1995;Kreutzberg, 1996;Minghetti and Levi, 1998;Stoll and Jander, 1999;Streit et al., 
1999). Nowadays microglia have been widely accepted as the resident 
immunocompetent cells in the CNS based on their activation and performance of 
several immune functions including induction of inflammation, cytotoxicity, and 
regulation of T-cell responses through presentation of antigens (Aloisi, 2001). 
 
2. Molecular aspects of microglia 
Microglia seem to be the only cell type in the CNS with the capacity of full 
immunocompetence. Resting microglia have a unique ramified morphology and 
consistently expresse the complement receptor type-3 (CR3; CD11b/CD18 complex) 
which is also expressed on the surface of hematogenous macrophages (Streit and 
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Kreutzberg, 1987).  Except CR3, microglia also express IgG receptors (CD16/CD32) 
and ionized calcium-binding adaptor protein-1 (IBA1) (Raivich and Banati, 2004). In 
some species, the T-helper lymphocytes accessory molecule, CD4 antigen, can also be 
found on activated microglia (Perry and Gordon, 1987). Microglia can react to various 
CNS injuries rapidly accompanied with the changing of morphology from ramified to 
amoeboid microglia, up-regulation of CR3 receptor, and a relative early sign of up-
regulation of MHC I and MHC II on the cellular surface which enable microglia to 
interact directly with immunocompetent cells such as T cells (Kreutzberg, 1996).  
Antigen presentation may be one of the most important functions of microglia. Strong 
up-regulation of antigen presenting accessory molecules, CD40 and B7.1 which is 
also called CD80, on microglia was reported in the multiple sclerosis (MS) (De et al., 
1995;Gerritse et al., 1996). Activated and phagocytic microglia also expressed 
costimulatory molecules such as ICAM (intercellular adhesion molecule)1-3, αXβ2 
integrin or B7.2 which is also called CD86 in a variety of pathological conditions (Bo 
et al., 1996;Kloss et al., 1999;Werner et al., 2001). Both brain-resident microglia and 
infiltrating macrophages express a large number of cell surface molecules that 
mediate cell adhesion including α4β1, αMβ2, αLβ2 and αXβ2 integrins (Cannella et 
al., 1991), galectin-3 (Reichert and Rotshenker, 1999), the CD200 receptor which 
could mediate the anti-inflammatory effects of the CD200 system (Hoek et al., 2000) 
and the leukocyte selectin which is also known as L-selectin or CD62L (Grewal et al., 
2001). These similarities between microglia and blood-borne macrophages make 
researchers focus more on the immune functions of microglia. Previous studies have 
indicated that both microglia and blood-borne macrophage were crucially involved in 
the immune response by acting as the antigen-presenting cells and secondarily 
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recruiting T cells, granulocytes and macrophages (Hickey and Kimura, 1988;Huitinga 
et al., 1995;Jones et al., 1999).  
 
3. Microglia in neurodegenerative diseases 
Neurodegenerative diseases such as Parkinson’s diseases (PD), Alzheimer’s diseases 
(AD), and amyotrophic lateral sclerosis (ALS) are main causes of disability, dementia, 
and death in people, especially those over age of 65 years (Ross and Poirier, 2004). 
Morphologically, neurodegenerative diseases are featured with progressive loss of 
neuronal population in some specific vulnerable areas in the CNS and often associated 
with intra-cytoplasmic and/or intra-nuclear protein aggregates formation (Jellinger, 
2003). Microglial activation is an early sign that often precedes neuronal death in 
chronic neurodegenerative diseases and increasing evidence has indicated that 
activated microglia could sustain a local inflammatory response in these chronic 
pathologies (Aarli, 2003;Ross and Poirier, 2004). Postmortem analysis showed the 
involvement of microglial activation in the substantia nigra (SN) of PD patients 
(McGeer et al., 1988).  Subsequent studies from other groups reported the presence of 
soluble factors and enzymes such as  tumor necrotic factor-α (TNF-α), interleukin-1β 
(IL-1β), IL-6, interferon gamma (IFN-γ) and inducible nitric oxide synthase (iNOS) 
which indicated the occurrence of inflammation in the SN (Liu et al., 2003). The 
presence of activated microglia surrounding beta-amyloid protein (Aβ) deposits in the 
AD patients as well as the ability to induce microglial phagocytic response by Aβ, 
both indicating that microglia may play an important role in the pathology of AD 
(Kopec and Carroll, 1998). In human immunodeficiency virus (HIV) associated 
dementia, microglia serve as the reservoir for viral replication, resulting in an 
upregulaion of expression of pro-inflammatory factors to exacerbate the progression 
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of the disease (Cosenza et al., 2002). Infection by HIV resulted in enhanced 
microglial activation and an increased production of pro-inflammatory factors 
(Sopper et al., 1996). In animal model of MS, microglia proliferated around the sites 
of demyelization and showed an increased lysosome activity (Matsumoto et al., 
1992b). More direct relationship between microglial toxicity and neurodegenerative 
diseases comes from chronic lipopolysaccharide (LPS) infusion in rat which induced 
a delayed, progressive and selective loss of nigral DA neurons (Gao et al., 2002b). 
However, while we are highlighting the microglial activation in various 
neurodegenerative diseases and presenting microglial neurotoxicity based on the 
animal model and in vitro experiment, how the microglial activation could result in 
the neurodegenerative pathology and if the microglial activation would be exclusively 
deleterious to the neurodegenerative patients or not still remains unclear.   
 
4. Dual functions of microglia 
Because microglia and macrophages share most phenotypical markers and can exert 
similar effecter functions, researchers now have considered microglia as the principal 
immune cells in the CNS (Gonzalez-Scarano and Baltuch, 1999). The function of 
microglia in the CNS had been contradictory for years: whether microglia are 
neuroprotective or neurotoxic when activated? Although it has been widely accepted 
that microglia can amplify the inflammatory effects and mediate cellular damages 
(Minagar et al., 2002), the widely accepted concept of pro-inflammatory and toxic 
microglial functions in chronic degenerative diseases such as AD, Creutzfeldt–Jakob 
(CJD), and PD mostly came from in vitro evidences that cultured microglial cells 
could acquire pro-inflammatory functions by producing inflammatory cytokines, 
reactive oxygen and nitrogen species and lipid mediators (McGeer and McGeer, 
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2001;McGeer and McGeer, 2002). On the other hand, resident microglia play a part in 
tissue repair after injury and synergistic effects of microglia and astrocytes are needed 
for tissue reconstitution after lesions such as controlling of the BBB (Blood Brain 
Barrier) and invasion of haematogenous cells as well as removing and downregulating 
pro-inflammatory cytokines (Streit and Kreutzberg, 1988). Although upon stimulation 
or under diseased/injury circumstances, microglia can release a variety of soluble 
factors, including some pro-inflammatory factors such as IL-1β (Bauer et al., 1993), 
TNF-α (Renno et al., 1995) and IL-6 (Frei et al., 1989;Puffenbarger et al., 2000), 
microglia can also produce other factors such as IL-10 (Jander et al., 1998), IL-4 and 
IL-13 as well as transforming growth factor β1 (TGF-β1) (Kiefer et al., 1998) which 
can suppress the immune response and are known as anti-inflammatory factors. 
Furthermore, the immunoreactivity of nerve growth factor (NGF) was detected in the 
resting ramified microglia (Krenz and Weaver, 2000) in normal rat. A double labeling 
of neurotrophin-3 (NT-3) with the OX-42 (marker for CR3 receptor) in post-natal 10 
day rats was also reported by Elkabes and his co-workers in 1996 which indicated the 
function of regulation of microglia on the neural development (Elkabes et al., 1996). 
Although extensive evidence has supported that the microglia are the main elements 
responsible for the pro-inflammatory and toxic activities, the studies on facial nerve 
axotomy showed that microglial neuroinflammation was a vital component of the 
regenerative process (Moran and Graeber, 2004;Streit et al., 1999).  Besides the 
inflammatory factors and neurotrophic factors, microglia can also release 
macrophage-colony stimulating factor (MCSF) (Hulkower et al., 1993), granulocyte-
macrophage colony-stimulating factor (GM-CSF), IL-12 and IL-23 which share the 
IL12p40 subunit (Bitsch et al., 1998;Cua et al., 2003;Fischer and Reichmann, 
2001;Laman et al., 1998;Li et al., 2003). In vitro studies showed that microglia were 
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also capable of secreting IL-15 (Hanisch et al., 1997) and IL-18 (Prinz and Hanisch, 
1999).  Based on previous studies, it is improper to classify microglia as exclusively 
beneficial or deleterious. It is likely that microglia can serve both functions depending 
on the progression of disease status and the type of stimulus.  
 
4.1. Microglial neuroprotective function 
Although bunches of experiments had been done regarding the microglia cytotoxicity 
upon activation, it is still not possible to classify the microglia as the exclusive 
destroyers. In contrast to the microglial toxic function by producing pro-inflammatory 
factors, microglia are also the source of growth factors such as TGF-β, platelet-
derived growth factor (PDGF), epidermal growth factor (EGF), insulin-like growth 
factors and basic fibroblast growth factor (bFGF), suggesting the microglia could 
potentially provide trophic support to other glial cells and neurons (Presta et al., 
1995;Rappolee et al., 1988a;Rappolee et al., 1988b;Shimojo et al., 1991). In the rat 
spinal cord autoimmune inflammation model, TGF-β1 was expressed in microglia on 
the recovery phase which indicates the immunosuppressive function of microglia 
during the recovery stage in the neuropathology (Kiefer et al., 1998). Previous studies 
also showed that microglia conditioned medium increased the survival of 
mesencephalic neurons and stimulated the myelination in vitro (Hamilton and Rome, 
1994;Nagata et al., 1993). Injection of in vitro cultured microglia into the blood 
circulation promoted the survival of neurons and enhanced the expression of brain-
derived neurotrophic factor (BDNF) and glial cell line-derived neurotrophic factor in 
the ischemic hippocampus in global brain ischemia model (Imai et al., 2007). Trophic 
factors such as nerve growth factor (NGF), BDNF and neurotrophin-3 (NT-3) have 
been demonstrated to be involved in the development and growth of the CNS and play 
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at least a partial role in the survival of neurons, proliferation of oligodendrocyte 
precursors and growth of axons (Arenas and Persson, 1994;Bradbury et al., 
1998;Davies et al., 1993;Yan et al., 1992). Therefore, microglia, as one of the 
potential resources of these neurotrophic factors, may be involved in the development 
of the CNS as well as play a protective role during certain phase of injuries or 
neuropathologies.  
 
4.2. Microglial cytotoxicity 
Inflammation in neurodegenerative diseases has now been implicated as a critical 
mechanism responsible for the neuron loss in the CNS (Block and Hong, 2005). 
Postmortem analysis revealed that reactive microglia were found to co-localize with 
the plaques in the cortical region of  AD patients and large numbers of reactive 
microglia with human leukocyte antigen (HLA-DR) positive immunoreactivity were 
found in the substantia nigra (SN) in which the degeneration of dopaminergic neurons 
was most prominent (McGeer et al., 1988;Rogers et al., 1988).   Microglia became 
activated in response to brain injuries, immunological stimuli and in 
neurodegenerative diseases ( Streit et al., 1988;Liu and Hong, 2003) and underwent 
morphological changes from resting ramified microglia into activated amoeboid 
microglia as well as expression and up-regulation of certain complement receptors 
and MHC molecules (Graeber et al., 1988;Oehmichen and Gencic, 1975).  In vitro 
studies showed that Aβ, the main component of insoluble extra-cellular plaques in AD, 
was able to recruit and activate microglia to release neurotoxic factors such as nitric 
oxide (NO), TNF-α and superoxide (;Ii et al., 1996;Sasaki et al., 1997;Qin et al., 2002; 
Dheen et al., 2005).  Pro-inflammatory factors released by activated microglia could 
function synergistically to induce inflammation-related neuronal damage (Jeohn et al., 
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1998). In the model of axotomy of the facial nerve in the transgenic mice, 
neutralization of endogenous TNF-α by overexpressing its soluble receptor (sTNFR1) 
decreased cell death of the injured facial motorneurons, suggesting that TNF-α may 
play an important role in neuronal degeneration in the CNS following nerve injury 
(Terrado et al., 2000). Under hypoxic condition, the activated microglia could induce 
obvious neuron death in vitro by producing NO (Mander et al., 2005). Among the 
factors, superoxide is also important for both the induction and amplification of 
neurotoxicity and it has been demonstrated that Aβ and rotenone could produce or 
enhance the neurotoxicity by generating superoxide (Gao et al., 2002a;Qin et al., 
2002).  
 
4.3. Microglial dual-function: when and why   
Now it have been widely accepted that microglia have both cytotoxic and 
neuroprotective functions. However, based on the long-list of factors secreted by 
microglia, it is very difficult to decide which factor or factors are functioning to 
determine the fate of microglia in neuropathogenesis of a neurodegeneratvie disease 
or nerve injury. Moreover, if the microglial functions, either toxic or protective, were 
mostly based on one or several factors that microglia have secreted in response to 
stimulation (Minghetti and Levi, 1998;Qin et al., 2002;Shimojo et al., 1991), the 
synergic effects of other factors would be excluded. It seems to be unreasonable to 
ignore so many other microglial factors, therefore one should have a broader view of 
this issue. Hence, the question of when and how activated microglia would 




5. Apoptosis and neuron death   
The loss of neuronal population is a major feature in many neurodegenerative diseases. 
Postmortem analysis of PD patient brain showed that the apoptotic cells as well as the 
DNA fragmentation were presented in the SN which indicated the possible 
involvement of apoptosis during neuronal degeneration (Anglade et al., 1997;Hirsch 
et al., 1999;Mochizuki et al., 1996). 
 
5.1. Apoptosis  
Apoptosis, also called programmed cell death, was first recognized during vertebrate 
development as part of a natural process to remove the unnecessary cell debris 
(Saunders, Jr., 1966). Roles of apoptosis later have been extended to morphogenesis, 
tissue homeostasis, immune regulation and the elimination of infected, mutated or 
damaged cells (Jacobson et al., 1997;Singh and Anand, 1995;Thompson, 1995). 
Morphologically, apoptotic cell death is characterized by the succession of chromatin 
condensation (pyknosis), nuclear fragmentation, cell contraction and decay into small 
fragments surrounded by plasma membrane (apoptotic bodies) (Bredesen et al., 
2006;Jellinger, 2006). Contraction of apoptotic cells can result in a decrease in cell 
volume, and alterations to the plasma membrane facilitating the recognition and 
phagocytosis of apoptotic cells by macrophages, thereby preventing an inflammatory 
response (Israels and Israels, 1999;Jellinger, 2006).  
 
5.2. Necrosis 
In contrast to apoptosis, another widely accepted cell death mechanism is necrosis 
(Israels and Israels, 1999). Necrotic cell death is characterized by the early loss of 
plasma membrane integrity following the plasma membrane leakage and leading to 
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increase in the content of intracellular fluid and subsequent swelling. The organelles 
of the necrotic cells also become swollen and finally disintegrated. The DNA 
becomes randomly fragmented and the entire cell undergoes lysis with the resultant 
spillage of intracellular contents into the surrounding tissues. The spillage of lytic 
enzymes could cause damage to the surrounding tissues and may lead to inflammation 
(Festjens et al., 2006). 
 
5.3. Involvement of apoptosis in neurological diseases 
Apoptosis has been implicated in many other human diseases such as AD, 
Huntington’s disease (HD), ischemic damage, autoimmune disorders, and several 
forms of cancers (Nicholson, 1996;Thompson, 1995).  Furthermore, apoptotic cells 
have been reported in various neural tissues including retinal ganglion cells (Quigley 
et al., 1995;Rabacchi et al., 1994), spinal motor neurons (Gu et al., 1997), sensory 
neurons (Groves et al., 1997) and facial nerve cells (de and Dubois-Dauphin, 1996) in 
neonatal and adult rodents after axotomy of the optic, sciatic and facial nerves, 
respectively. Although all the evidence indicates that apoptosis may be responsible for 
the neuronal loss in vivo, the cause for apoptosis still need to be further investigated.   
 
5.4. Microglial cytotoxicity induced apoptosis 
Microglial activation has been reported to be responsible for the neuron loss based on 
the in vitro studies. Among the wide range of factors released by activated microglia, 
some of them could trigger  apoptosis in neuronal culture (Bessis et al., 2007).  Piani 
and co-workers reported that murine microglia could secrete glutamate to induce 
NMDA-receptor-mediated apoptosis in neuron culture (Piani et al., 1991).  TNF-α 
produced by activated microglia caused apoptosis in cerebellar granule cells through 
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Fas ligand (FasL) (Taylor et al., 2005). It was also reported that NO and IL-1β could 
induce apoptosis in mixed spinal cord culture (Chao et al., 1992;Tikka and Koistinaho, 
2001). More evidences came from the induction of apoptosis by microglia-secreted 
reactive oxygen species and TNFα in neuronal cortex culture (Colton and Gilbert, 
1987;Floden et al., 2005).  All these studies have indicated that microglia are at least 
partially responsible for the neuronal apoptosis and this cytotoxic function might be 
mainly mediated by the factors produced by microglia due to the stimuli (Bessis et al., 
2007).  
 
5.5. Caspases and two apoptosis pathways 
The morphologic and biochemical changes during apoptotic cell death are mediated 
by a family of intracellular cysteine proteases named caspases (cysteine aspartyl-
specific proteases), which cleave their substrates at aspartate residues (Alnemri et al., 
1996;Suzuki and Shiraki, 2001). The caspases are usually divided into upstream 
initiator caspases and downstream effector caspases and the regulation of the activity 
of these caspases have been shown to be able to affect the cell fate (Reed, 1995). Now 
it has been widely accepted that two main pathways can activate the effector caspases: 
one is death-receptor pathway (Thorburn, 2004) and the other is mitochondrial 
pathway (Gottlieb, 2000).  Despite the difference in the initiation of this two pathways, 
they converge on the activation of effector caspases (Jin and El-Deiry, 2005). 
 
5.5.1. Death-receptor activated apoptosis 
The apoptotic pathway activated by ligand-bound death-receptor such as TNF, Fas or 
Trail receptors has been implicated in many human diseases. The apoptotic processes 
mediated by death receptor pathway are better understood than that of mitochondria-
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mediated apoptototic pathway (Ashkenazi and Dixit, 1998;Ashkenazi and Dixit, 
1999). Upon ligand binding to death receptors, activated death receptors recruit an 
adaptor protein called Fas associated death domain (FADD) which consists of two 
protein interaction domains: a death domain and a death effector domain (DED) 
(Chinnaiyan et al., 1995). FADD can bind directly or via another adaptor such as TNF 
receptor associated death domain (TRADD), which binds to TNFR1 and recruit pro-
caspase-8 through DED interactions to form a complex at the receptor called the death 
inducing signalling complex (DISC). Recruitment of caspase-8 through FADD leads 
to its auto-cleavage and activation (Salvesen and Dixit, 1997). Active caspase-8 in 
turn activates effector caspases such as caspase-3 and causes the cell to undergo 
apoptosis by digesting upwards of a hundred or so proteins (Fischer et al., 2003).  
 
5.5.2. Mitochondria-mediated apoptosis 
The mitochondrion is not only the powerhouse of a cell but it also contains some pro-
apoptotic proteins. In mammalian cells, the intracellular communication may involve 
the translocation of different proteins to the mitochondrion such as Bcl-2 and Bax 
from endoplasmic reticulum, Bcl2-interactiong mediator (Bim) from cytoskeleton and 
Bcl2-associated X protein (Bax), Bcl-2 homologous antagonist/killer (Bak) and BH3 
interacting domain death agonist (Bid) from the cytosol. And these translocation may 
result in the modification of the permeability of mitochondria (Olson and Kornbluth, 
2001;Regula et al., 2003). Increased permeability of outer mitochondrial membrane 
may lead to release of cell-death activators, inhibitors and inhibitor derepressors such 
as cytochrome c, apoptosis-inducing factor (AIF) (Susin et al., 1999) and 
Smac/DIABLO (Smac: Second mitochondria-derived activator of caspases; DIABLO: 
direct inhibitor of apoptosis protein-binding protein of low isoelectric point) (Chai et 
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al., 2000). Previous studies have revealed that the release of cytochrome c from the 
mitochondria together with the adaptor protein apoptotic protease activating factor 1 
(apaf-1) was required for the activation of caspase-9 and in turn recruited and 
activated the effector caspases responsible for ordered disassembly of the cell (Li et 
al., 1997). Smac/DIABLO could facilitate caspase activation by inhibiting proteins 
from the inhibitor of apoptosis protein (Iap) family, such as X-linked inhibitor of 
apoptosis protein (Xiap), which are caspase inhibitors (Du et al., 2000) and apoptosis-
inducing factor (AIF) was thought to play a role in the induction of caspase-
independent apoptotic changes in the nuclei (Susin et al., 1999). 
 
5.6. Key regulators of mitochondria-mediated apoptosis 
While the initiation and execution of apoptosis depend on activation of the receptor- 
and/or mitochondrial-dependent death pathway, the process of apoptosis is affected 
by many other factors. And the crosstalk between the death-receptor pathway and 
mitochondrial pathway has been reported (Li et al., 1998). Among all the regulatory 
factors of apoptosis, Bcl-2 family members seem to play an very important role in 
regulating the mitochondria-mediated apoptosis (Mohamad et al., 2005;Murphy et al., 
2005). 
 
5.6.1. Bcl-2 family  
A typical event in the mitochondrial apoptosis pathway is the change of mitochondrial 
outer membrane permeabilization (MOMP). Previous studies showed that the MOMP 
was mainly mediated and controlled by Bcl-2 family members (Green and Kroemer, 
2004). The Bcl-2 protein was firstly discovered in B-cell lymphomas (Tsujimoto et al., 
1985). In 1990, the Bcl-2 was first indicated as a mitochondrial membrane protein and 
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overexpression of it could block apoptosis (Hockenbery et al., 1990). After an 
explosion of studies on Bcl-2 family, more and more Bcl-2 family members have 
been discovered. Bcl-2 defines a family of proteins that contains both pro- and anti- 
apoptotic members. Anti-apoptotic members including Bcl-2, Bcl-w, Bcl-xL and Mcl-
1 contain all the 4 Bcl-2 homology (BH) domains whereas pro-apoptotic members 
such as Bax, Bok and Bak contain the BH1, BH2 and BH3. There are also some pro-
apoptotic members that contain only the BH3 domain and are referred as “BH3-only” 
proteins including Bad, Bid, Bim and others (Murphy et al., 2005). Bcl-2 family 
members could interact with itself or several other different members and form 
homodimer or heterodimer to block each other’s next move (Antonsson and Martinou, 
2000;Reed, 1997). Several competing hypotheses have suggested that some Bcl-2 
members can translocate into the mitochondrial outer membrane and form channels or 
large pores to facilitate the leaking of cytochrome c, AIF or Smac/DIABLO from 
mitochondria (Loeffler and Kroemer, 2000;Muchmore et al., 1996;Shimizu et al., 
1999). Bcl-2 family members were also reported to possess the abilities of direct 
regulation of activation of caspases via adaptor molecules such as Apaf-1 (Zhou et al., 
1999), BAR (Zhang et al., 2000), endoplasmic reticulum-localized protein Bap31 (Ng 
et al., 1997) and Aven (Chau et al., 2000).   
 
5.6.2. Bcl-2 family members in neuron death 
The Bcl-2 family of proteins has been shown to regulate neuronal cell death during 
development. The alteration in the expression of Bcl-2 family members in 
neurodegenerative diseases including AD, HD, PD and ALS has also been reported 
(Shacka and Roth, 2005). Hartmann et al. reported that Bax was expressed 
ubiquitously by DA neurons in post-mortem brain of PD patients as well as in vitro 
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cell culture. Furthermore, Bax was found inserted into the outer mitochondrial 
membrane as an index of Bax activation (Hartmann et al., 2001). It has also been 
shown that in neurons, the calcium-activated phosphatase calcineurin de-
phosphorylated the pro-apoptotic protein Bad and initiated the apoptosis cascade 
(Wang et al., 1999). On the other hand, neurons from mice deficient of the BH3-only 
protein Bid have been shown to be resistant to ischemic injury in vivo and hypoxic 
and excito-toxicity in vitro (Plesnila et al., 2001;Plesnila et al., 2002). It is apparent 
that the Bcl-2 family proteins play an integral part in the apoptotic pathways in 
neurons. The more detailed understanding of functions of each Bcl-2 family members 
and the pathway under influence of microglial dual function would gain new insight 
into the regulation of neuron death and provide new cue for the exploration of therapy 
strategies.  
 
5.6.3. Diva, a new identified Bcl-2 family member 
In 1998, Inohara and co-workers have reported a novel Bcl-2 family member. Its gene 
was cloned from the GenBank expressed-sequence tag (EST) which was homology to 
chicken neuroretina (NR-13). Analysis of its nucleotide sequence revealed an open 
reading frame (ORF) encoding a protein of 191 amino acids. The new protein was 
designated as Diva (death inducer binding to vBcl-2 and Apaf-1) (Inohara et al., 
1998). In 1999, another group also reported a new identified novel Bcl-2 family 
member gene which is homologue to NR-13 as well and the protein was named 
as Bcl-2 homologue of ovary (Boo) (Song et al., 1999). Both groups showed that the 
novel Bcl-2 family protein was highly homologous to Bcl-2, Bcl-w and Bcl-xL 
(Inohara et al., 1998;Song et al., 1999). Although the new genes, Diva and Boo, have 
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been reported by two different groups respectively, the genes were later found 
identical to each other (Song et al., 1999).   
5.6.3.1. Structure of Diva 
Sequence analysis revealed that Diva contains all four Bcl-2 homology domains (BH1, 
BH2, BH3 and BH4) as well as a carboxyl-terminal hydrophobic (TM) domain. Diva 
showed significant structural and amino acid homology with all known Bcl-2 family 
members including Bcl-2, Bcl-xL, Bcl-w, Bax, Bak, Mtd and Caenorhabditis elegans 
CED-9. Although Diva was homologous (46% similar) to NR-13, it was suggested 
that Diva should not be the mouse orthologue of NR-13 because of the significant 
difference in some critical residues (Inohara et al., 1998).   
 
5.6.3.2. Distribution of Diva in vivo 
By in situ hybridization (ISH) and Northern blot as well as reverse transcription PCR 
(RT-PCR) analyses, Inohara et al. (1998) reported that Diva was found to be 
expressed only in adult ovary and testis in the mouse. Hybridization with a probe to 
Diva revealed undetectable expression in the brain, liver, heart, lung and spleen in the 
mouse. However, in E15 embryo, intense Diva mRNA labeling was detected in the 
brain, liver and heart (Inohara et al., 1998). Similar results were also found by Song et 
al when locating the expression of Boo in the mouse tissues by using Northern blot. 
The expression of Boo was found undetectable or at very low levels not only in the 
heart, brain, spleen, lung, liver, skeletal muscle and kidney but also in the testis, and 
no expression was found during embryonic development from E7 to E17 in mouse 
(Song et al., 1999).  Both papers used the Northern blot but the expressions of Diva in 
testis and E15 embryo were opposite and this may be caused by the specificity of the 
probes. The contradiction lies in the expression of Diva in the adult testis and the E15 
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embryo between these two papers, indicating that the expression of Diva in vivo still 
need to be further clarified. Furthermore, in human, Bcl-B, the homologue of Diva, 
was found expressed in numerous organs including heart, brain, lung, liver, pancreas, 
thymus, colon, intestine, testis, prostate, ovary and spleen (Ke et al., 2001). Based on 
previous studies, the distribution of Diva in vivo still needs to be further confirmed, 
especially the distribution of Diva in the CNS. The CNS is composed of cerebrum, 
cerebellum, brain stem and spinal cord. Both authors did not mention which parts 
their samples came from. Furthermore, the expression level of Diva and sensitivity of 
Northern blot may also contribute to the inconsistency between these two papers.  
 
5.6.3.3. Function of Diva in apoptosis 
Except for the distribution of Diva in vivo, the function of Diva during the apoptosis is 
also contradictory. Diva was first reported as a pro-apoptotic factor during apoptosis 
and could bind directly to Apaf-1 resulting in a BH3-independent cell death (Inohara 
et al., 1998). However, Boo was reported to be able to inhibit apoptosis and 
homodimerize or heterodimerize with some pro-apoptotic Bcl-2 family members 
including Bax and Bik (Song et al., 1999). Further evidence supporting the anti-
apoptotic property of Diva came from Weller and co-workers who reported that 
Diva/Boo was a negative regulator of cell death and could inhibits apoptosis in glioma 
cells induced by CD95 ligand or chemotherapeutic drugs (Naumann et al., 2001). In 
human, the homologue of Diva, Bcl-B, was found to inhibit the Bax induced 
apoptosis (Ke et al., 2001). Therefore, the function of Diva/Boo during apoptosis is 
still contradictory. Two opposite functions have been reported by different groups. 
Although there was the possibility that Diva might play a different role in different 
circumstances, it had never been reported that any other Bcl-2 family members can 
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play both anti-apoptotic and pro-apoptotic functions at the same time. Further 
clearification on this issue should be done. 
 
5.6.4. Bcl-2 family members in cell cycle 
The cell composition of an organ is determined by the rate at which cells proliferate, 
differentiate and die (Bonnefoy-Berard et al., 2004). The stimulation of cell 
proliferation would also inhibit the cell differentiation and sometime induce cells to 
undergo apoptosis (Askew et al., 1991;Askew et al., 1993). Although Bcl-2 family 
members have been known as the key players in the control of apoptosis, their 
overexpression in cell lines or in transgenic animals revealed that they are also 
involved in the control of cell proliferation (Linette et al., 1996;Winter et al., 1998). 
After the growth factor was withdrawn, the surviving cells were found to be in the 
quiescent state with an upregulated Bcl-2 protein level, suggesting connection 
between Bcl-2 and cell-cycle(Vaux et al., 1988). Later, the anti-proliferative effect of 
Bcl-2 has been reported as being shared by other Bcl-2 family members including 
Bcl-xL (O'Reilly et al., 1996), Bcl-w (Huang et al., 1997) and Mcl-1 (Fujise et al., 
2000). While the anti-apoptotic members of the Bcl-2 family could arrest the cell in 
the G0/G1 phase, overexpression of the pro-apoptotic Bax protein could result in an 
increased number of cycling thymocytes (Brady et al., 1996). Moreover, it has been 
demonstrated that the anti-proliferative effects of Bcl-2 protein could be counteracted 
by Bax (Borner, 1996). All these observations demonstrate that overexpression of 
pro- and anti-apoptotic members of the Bcl-2 family could affect cell-cycle in an 




6. Cell cycle and stem cell differentiation 
Stem cells have the capacity of unlimited proliferation while retaining the potential to 
differentiate into a wide range of cell types. The cell cycle of stem cells is unusual 
characterized with a very short G1 phase and a high proportion of cells in S-phase 
(White and Dalton, 2005). As stem cells differentiate, their cell cycle structure 
changes dramatically and incorporates a significantly longer G1 phase (Sommer and 
Rao, 2002). These unique cell cycle structure and regulation mechanisms of stem cells 
indicate that the cell cycle regulation may play an important role during stem cell 
differentiation.  
 
6.1. Neural stem cells 
In adult animals, various tissues contain stem cells such as bone marrow, skeletal 
muscle, intestine, liver, epidermis, peripheral nervous system (PNS) and retina. 
However, it has been long believed that stem cells do not exist in the CNS  (Hall and 
Watt, 1989;Potten and Loeffler, 1990). Nowadays, it is evident that the developing 
and adult CNS also contain a population of undifferentiated multi-potent cell 
precursors, the neural stem cells (Ourednik et al., 1999).  These cells are defined by 
their ability of self-renewal and by their potential to differentiate into various neuronal 
and glial cell lineages (Ourednik et al., 1993). These properties of neural stem cells 
made it a promising target for more effective therapeutic application in neurological 
disorders including neurodegenerative diseases. For example, by transplanting fetal 
mesencephalic cells into patients with PD, long-lasting symptomatic improvement 
was observed (Vescovi and Snyder, 1999) . Neural stem cells can be maintained in a 
proliferative state in vitro by chronic mitogen stimulation or co-culture on various 
cellular membrane substrates.  Under certain culture circumstances, the neural stem 
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cells can withdraw from the cell cycle and differentiate into some, if not all, neuronal 
and glial cell types (Gage et al., 1995;Ishikawa, 1977).  
 
6.1.1. Neural stem cells in vivo and in vitro 
Neural stem or progenitor cells are capable of self-renewal and differentiation into 
multi-cell lineage, have been identified in specific regions in the adult brain: in 
particular the hippocampal subgranular zone and the subventricular zone (SVZ). 
These neural stem cells can give rise to new neurons which are able to migrate to the 
dentate gyrus and the olfactory bulb, respectively (McKay, 1997;Weiss et al., 1996). 
SVZ cells grown in the presence of growth factors such as epidermal growth factor 
(EGF) or/and fibroblast growth factor (FGF-2) give rise to floating clusters of cells 
called neurospheres (Lois and varez-Buylla, 1993). The neurosphere cells are capable 
of differentiating into neurons, astrocytes and oligodendrocytes in vitro and following 
transplantation as well (Gage, 2000). Other than direct culture from the adult SVZ, 
embryonic stem (ES) cells were also used to differentiate into NSCs (Ying et al., 
2003). Another alternative to use ES cell-derived NSCs is to directly isolate NSCs 
from the embryonic CNS. The NSCs obtained by this way were also called embryonic 
NSCs (Bithell and Williams, 2005). In addition, more restricted multipotential neural 
progenitor cells (NPC) with the capacity to give rise to both neuronal and glial 
progeny in vitro have been isolated from numerous adult brain regions in both rodents 
and humans (Arsenijevic et al., 2001;Nunes et al., 2003;Pagano et al., 2000;Roy et al., 
2000b;Roy et al., 2000a). No matter where the NSCs were derived from, they all have 
the ability to self-renew and can give rise to neurons, astrocytes and oligodendrocytes 
(Gage, 2000).  
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6.1.2. Bcl-2 family members and neural stem cells 
Bcl-2 family members have been known for their important regulatory function 
during apoptosis. It was reported that mice deficient in Bax and its related family 
member Bak have increased numbers of periventricular neural precursor cells 
(Lindsten et al., 2000;Lindsten et al., 2003). This evidence has demonstrated the 
possible involvement of Bcl-2 family members in the survival of neural stem cells. 
Because stem cells have the ability of self-renewal and can keep on proliferating 
under proper environment in vitro which means stem cells could be continuously in 
the cycling state, the regulation of cell cycle should play important role during the 
stem cells differentiation which is accompanied with withdrawing from the cell cycle. 
It have been reported that pro-apoptotic members of Bcl-2 family could arrest cell in 
the G0/G1 phase and overexpression of Bax could counteract this effect (Borner, 
1996;Brady et al., 1996). It is reasonable to hypothesize that members of Bcl-2 family 
might also play an important role during the neural stem cell differentiation by 
facilitating or inhibiting their exit from the cell cycle. 
 
7. Hypothesis 
The activation of microglia has been studied for a long time. Previous studies have 
indicated that microglia either play a neuroprotective or neurotoxic role after 
activation. Postmortem studies showed that the distribution of activated microglia is 
more concentrated in the diseased foci than the peripheral areas. Moreover, in vitro 
studies showed that the activation of microglia response to different stimuli was 
mostly time- and concentration of stimulus-dependent. Activated microglia could 
release various factors and among these factors, individual ones could present 
opposite effect on neurons. It is therefore reasonable to hypothesize that the overall 
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temporal and spatial distribution of total microglia-released factors, not individual 
ones, would be responsible for microglial dual functions. It implies that the balance 
between co- and counter-effects of various microglial factors might determine the 
protective/trophic or destructive/toxic role of microglia in a given disease or injury 
circumstance. 
 
Bcl-2 family members have been widely believed to be the important regulators of 
apoptosis. They can either protect cells from death or facilitate the progress of 
apoptosis. Different members play different roles under different circumstances. 
Because Bcl-2 family includes both anti-apoptotic and pro-apoptotic members, it is 
reasonable to hypothesize that Bcl-2 family members might respond differentially to 
result in either protection of neurons from the microglial cytotoxicity or facilitation of 
neuronal deaths.  
 
In consideration of possible roles of Bcl-2 family members in apoptosis and cell cycle, 
it is reasonable to assume that their expressions may be functionally important for 
stem cell survival, self-renewal and differentiation after they are transplanted into the 
CNS.  In vivo, the transplanted stem cells will interact with various cells including 
microglial cells. Information about Diva’s expression in the stem cells may be 
important for future study on the role of the Diva in the stem cells under microglial 






8. Aims and scopes 
8.1. To identify the possible relationship between microglial activation and its 
dual function in vitro. 
It is still unclear why microglia could exert opposing functions, namely 
neuroprotection/neurotrophy and neudestruction/neurocytotoxicity. Most studies are 
focused on one or several microglial cytotoxic or neurotrophic factors to evaluate the 
microglial function under certain circumstances. However, the cause which makes 
microglia exert its toxic or protective function is still unclear. It is not possible to 
decide the microglial overall function by only focusing on one or several factors. In 
the present study, microglial dual functions will be elucidated using a more global 
view to investigate the interactions between microglia and motoneurons in vitro and 
in vivo.   
 
8.2. To verify microglial protective or destructive function in protein aggregate-
containing neuron model in vitro 
Intracellular protein aggregates in neurons have been widely discovered in different 
kinds of neurodegenerative diseases and are believed to be involved in the 
neuropathogenesis. The formation of protein aggregates in the neurons and activation 
of microglia have been believed to be a chronic process in neurodegenerative diseases. 
However, the effects of activated microglia on the formation of protein aggregates 
still remain unclear. In the present study, the effects of activated microglia on the 




8.3. To identify the possible involvement of Bcl-2 family members in neurons 
during the interaction between microglia and neurons 
Microglia can either cause apoptosis in neurons or protect neurons from death. Bcl-2 
family members are the key regulators during apoptosis and are characterized as 
either anti-apoptotic or pro-apoptotic. Although Bcl-2 family members during the 
apoptosis of neurons have been studied frequently, there are still case by case 
differences. In the present study, the expression of Bcl-2 family members in the 
culture system will be investigated, and the more significant Bcl-2 family proteins 
involved in apoptosis will be studied in more details. 
 
8.4 To study Diva in animal and cell models  
8.4.1 To investigate the distribution of Diva in the CNS 
As one of the newly identified Bcl-2 family members, the distribution of Diva in the 
CNS is still remain unclear. Although previous studies have indicated that the 
expression of Diva was not obersved in the brain, the detailed map of Diva’s 
expression in the CNS is not clear. In the present study, the expression of Diva in the 
CNS will be detected in various regions of the brain such as cerebrum, brain stem and 
spinal cord. 
 
8.4.2. To evaluate the possible role of Diva in response to microglial cytotoxicity  
As one of the Bcl-2 family members, Diva has been reported to play either anti-
apoptotic or pro-apoptotic function in the regulation of apoptosis by different 
researchers. Although it is possible that Diva may really possess both anti- and pro-
apoptotic properties which are different from other Bcl-2 family members, it is more 
reasonable that Diva could play different roles under different situations. In the 
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present study, the role of Diva in the regulation of apoptosis of NSC-34 neurons in 
response to microglia cytotoxicity will be investigated. 
 
8.4.3 To evaluate the possible role of Diva during the cell cycle regulation in both 
NSC-34 and neural stem cells 
Bcl-2 family members have been shown that they not only regulate apoptosis, but also 
regulate the cell cycle. Previous studies indicated that several Bcl-2 family members 
were involved in the regulation of cell cycle (Bonnefoy-Berard et al., 2004;Linette et 
al., 1996;Winter et al., 1998). It was reported that the anti-apoptotic members of Bcl-2 
family facilitate the exit of cells from the cell cycle and inhibit cell proliferation 
whereas pro-apoptotic members can keep cells in the cell cycle and promote cell 
proliferation. However, the function of Diva in the regulation of cell cycle has never 
been investigated. In the present study, the effects of Diva on the proliferation of 
NSC-34 cells will be investigated and it would be even more interesting to determine 
if Diva plays any role in regulating the neural stem cell cycle which is linked to neural 
stem cell differentiation. Due to the time limitation, this study could only provide 
some fundamental information for the future study on the issue of effects of 



































I: Determination of Microglial Dual Functions by the Concentrations 

















Microglia, distributed ubiquitously throughout the CNS, serve as a pathological 
sensor and can respond rapidly to injuries or stimuli resulting in their activation 
(Kreutzberg, 1996). Activated microglia serve as scavenger cells by gradually 
increasing in numbers, migrating towards injury sites or invaded pathogens and 
transforming from resting ramified cells to phagocytotic amoeboid cells (Kim and de, 
2005). In addition to upregulation of surface receptors or antigens such as 
complement receptor type 3 (CR3) and major histocompability complex type II 
(MHC-II), activated microglia can also release or upregulate a long list of cytokines, 
chemokines and enzymes such as IL-1β, IL-6, TNF-α, TGF-β1, M-CSF, iNOS, NGF, 
neurotrophin-3, and BNDF (Bradbury et al., 1998;Hao et al., 2001;Hao et al., 
2002;Nakajima et al., 2001a). Based on the numerous studies that have been carried 
out until today, it has been widely accepted that that microglia play important roles in 
homeostasis and pathogenesis in the CNS. 
 
Microglia-released cytokines, chemokines and enzymes are very important in 
microglial functions as well as in modification of peri-neuronal microenvironment. 
For instance, IL-1β has been shown to mediate general inflammatory responses that 
promote further secretion of pro-inflammatory cytokines such as IL-6, IL-8, CSF, and 
TNF-α (Ehrlich et al., 1998). The recombinant IL-1 receptor antagonist has been 
reported to be able to significantly reduce the degree of damage following brain injury 
(Toulmond and Rothwell, 1995). Previous studies also indicated that TNF-α had a 
prominent chemotactic effect and could induce an increased expression of cell surface 
antigens as well as intercellular adhesion molecule-1 (ICAM-1) in endothelial cells 
and astrocytes (Shrikant et al., 1996). This may be directly related to the observed 
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migration of inflammatory cells into the CNS following spinal cord injury (Isaksson 
et al., 1999). TNF-α and other unknown factor(s) released from LPS-activated 
microglia not only could lead to a significant loss of motoneurons in vitro (He et al., 
2002), but also could be directly cytotoxic to oligodendrocytes in vitro and induce 
significant demyelination in vivo (Mastronardi et al., 2006;Probert et al., 1995). 
Furthermore, upregulation of M-CSF and its receptors in neuron-injury-activated 
microglia has been suggested to augment the overall inflammatory response and result 
in further damages to neurons (Hao et al., 2002). Based on the previous studies, it is 
reasonable to hypothesize that the inhibition of microglial activation could possibly 
attenuate neuronal degeneration induced either by ischemia (Giulian and Robertson, 
1990) or by excitatory neurotoxin (Coffey et al., 1990).  
 
On the other hand, activated microglia have also been reported to possess 
neuroprotective/neurotrophic effects in vitro and in vivo. Activated microglia could 
release IL-1α and IL-6 and protect neuronal cell lines from hydrogen peroxide-
induced oxidative attacks (Bissonnette et al., 2004). As early as 1993, Nagata et al. 
have reported that microglial conditioned medium could support the survival of 
explanted embryonic rat mesencephalic neurons (Nakajima et al., 1993). Another 
evidence of microglial neuroprotective function is that direct application of cultured 
BV-2 microglia cells to the hippocampus slice cultures could save more neurons after 
deprivation of oxygen and glucose (Neumann et al., 2006). In vivo, transplanted 
microglial cells were found to facilitate neuronal growth in the injured site of the CNS 
(Kitamura et al., 2004). Furthermore, the secretion of neurotrophic factors including 
NGF, NT-3 and BNDF by activated microglia has been demonstrated by previous 
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studies, indicating that these factors may be involved in microglial protective function 
(Nakajima et al., 2001b;Nakajima and Kohsaka, 2004).   
 
A previous study has indicated that microglial TNF-α required some other microglial 
factors to kill neurons (He et al., 2002), it is therefore assumed that the balance 
between toxic and trophic effects of various microglial factors may determine the role 
of microglia under a given disease or injury condition. In the present study, the dual 
functions of microglia which have been activated using lipopolysaccharide (LPS) on a 
motor neuron cell line (NSC-34) have been investigated. The neurotoxin, 2,5-
hexanedione (HD), was applied to motor neurons in vitro to produce neuropathies 
characterized by large axonal swelling associated with multifocal aggregates of 
neurofilaments which show some similarity in certain neurodegenerative disease in 
vivo and in vitro (Graham et al., 1995;Hartley et al., 1997;LoPachin et al., 2005).  
 
2. Materials and methods 
2.1. Tissue cell culture 
2.1.1. NSC-34 motoneuron cell line 
NSC-34 cell line is a mouse motoneurons cell line generated by fusing the 
aminopterin-sensitive neuroblastoma with motor neuron-enriched embryonic day 12-
14 spinal cord cells (Cashman et al., 1992). It expresses a number of morphological 
and biological properties of motoneurons including cholinergic function, expression 





2.1.2. BV2 microglial cell line 
The BV-2 cell line is an immortalized murine microglial cell line and has been widely 
used in various experimental settings. Recently, by using microarray analysis, BV-2 
cell line has been further proven as a reliable microglial cell line that shows some 
microglia-specific properties when stimulated with LPS, Dopamine (DA) quinone, 
and TAT (He et al., 2002;Lunemann et al., 2006;Roy et al., 2006).  
 
2.1.3. Maintenance of NSC-34 and BV2 cell line 
NSC-34 and BV-2 cells were routinely maintained at 37°C and 5% CO2 in DMEM 
(Sigma, USA) supplemented with 10% heat-inactivated fetal bovine serum (FBS) 
(Hyclone, Germany).   
 
2.2. Activation of BV-2 cells by Lipopolysaccharide 
After the BV-2 cells have grown to 100% confluence in DMEM plus 10% heat-
inactivated FBS, the culture media were discarded and the BV-2 cells were washed 
with PBS twice. Then the BV-2 cells were exposed to 5, 10, 100, 500ng/ml and 
1μg/ml LPS (L6529, Escherichia coli 055:B5, Sigma, USA) respectively in DMEM 
without serum for different time intervals (1, 4, 8, 12, and 24 hours). Then the LPS 
stimulated BV-2 conditioned media (LPS-BVCM) were collected, centrifuged, 
filtered through 0.22μm filter and stored at -80°C before use.  
 
2.3. Investigation of pro-inflammatory factors by ELISA assay  
To assess if there is any difference in the onset time of upregulation or in the amount 
of cytokines released from LPS-activated microglia, the amount of mouse TNF-α, IL-
1β and IL-6 were detected in the supernatant by ELISA kits (Pierce, USA). Briefly, 
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different concentrations of LPS stimulated BV-2 conditioned media were collected 
from 75cm2 flasks and filtered. Fifty microliters sample was added into each well on 
an anti-TNF-α, anti-IL-1β or anti-IL-6 pre-coated 96-well strip plate. After 1 hour’s 
incubation at room temperature, the plates were washed for three times by washing 
buffer. Fifty microliters biotinylated antibody reagent was added into the sample and 
incubated at room temperature for another 1 hour.  After washing with the washing 
buffer for three times, 100 μl of streptavidin-HRP reagent was added into each well 
and incubated at room temperature for 30 minutes. The plates were washed with 
washing buffer for three times again before 100 μl TMB substrate solution was added 
into each well. After 10 minutes incubation in dark at room temperature, 100 μl stop 
solution was added into each well to stop the color reaction and the absorbance at 450 
nm and 550 nm of each well were read by a plate reader. The concentrations of TNF-
α, IL-1β and IL-6 were calculated based on the standard curve. 
 
2.4. Treatment of NSC-34 cells with LPS-BVCM or LPS 
The NSC-34 cells were collected from 75-cm2 flask and washed with DMEM/F12 
twice before seeding into the 96-well plate at 4x104cells/well. Twenty-four hours after 
the seeding, 10%, 25%, 50%, 75% and 100% of LPS-BVCM in DMEM/F12 were 
added into the NSC-34 cells respectively. After 36 hours of treatment, the viabilities 
of the NSC-34 cells were measured by MTS assay using CellTiter 96® AQueous Non-
Radioactive Cell Proliferation Assay Kit (Promega, USA) following the manufacturer 
instruction. The NSC-34 cells cultured in DMEM/F12 for 36 hours served as control. 
At the same time, the toxicities of LPS alone on the NSC-34 cells were also 
investigated. The NSC-34 cells were treated with different concentrations of LPS 
corresponding to the different concentrations of LPS in 10%, 25%, 50%, 75% and 
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100% of 1μg/ml LPS-BVCM in DMEM/F12 (i.e. 100, 250, 500, 750ng/ml and 
1μg/ml  LPS in DMEM/F12) for 36 hours. The viabilities of the NSC-34 cells were 
also measured by MTS assay. 
 
2.5. 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-
2H-tetrazolium (MTS) viability assay 
MTS assay was employed to investigate the viability of NSC-34 cells after various 
treatments. The CellTiter 96® AQueous Non-Radioactive Cell Proliferation Assay is 
composed of solutions of a novel tetrazolium compound (3-(4,5-dimethylthiazol-2-
yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt; MTS) 
and an electron coupling reagent (phenazine methosulfate; PMS). MTS is bioreduced 
by dehydrogenase enzymes found in metabolically active cells into aqueous formazan 
product that is soluble in tissue culture medium. The absorbance of the formazan at 
490nm can be measured directly from 96-well plates and is directly proportional to 
the number of living cells in culture. After NSC-34 cells in 96-well were treated with 
the different concentrations of BVCM for 36 hours, 20μl of MTS solution were added 
into 100μl culture medium each well and incubate at 37℃ in dark for 4 hours. Then 
the absorbance of formazan at 490nm was read using an ELISA plate reader. The 
viability of each sample was determined using the following equation:  
 
(SampleOD490-BlankOD490) 






2.6. Apoptosis assays 
Apoptosis is characterized by a variety of morphological features such as loss of 
membrane asymmetry and attachment, condensation of the cytoplasm and nucleus, 
and internucleosomal cleavage of DNA. One of the earliest indications of apoptosis is 
the translocation of the membrane phospholipid phosphatidylserine (PS) from the 
inner to the outer leaflet of the plasma membrane. Once exposed to the extracellular 
environment, binding sites on PS become available for Annexin-V, a 35-36 kDa Ca2+-
dependent phospholipid binding protein with a high affinity for PS. The translocation 
of PS precedes other apoptotic processes such as loss of plasma membrane integrity, 
DNA fragmentation, and chromatin condensation. As such, Annexin-V can be 
conjugated to FITC and used for identification of cells in early stages of apoptosis. 
Because PS translocation also occurs during necrosis, Annexin-V is not an absolute 
marker of apoptosis. Therefore, it is often used in conjunction with propidium iodide 
(PI), which binds to nucleic acids, but can only penetrate the plasma membrane when 
membrane integrity is breached, as occurs in later stages of apoptosis or in necrosis. 
Cells that are negative for both Annexin-V and PI (Annexin-/PI-) have no indications 
of apoptosis. Cells with Annexin-V-positive and PI-negative (Annexin+/PI-) are in 
early apoptosis as PS translocation has occurred, yet the plasma membrane is still 
intact. And cells that are positive for both Annexin-V and PI (Annexin+/PI+) are 
either in late stages of apoptosis or are already dead, as PS translocation has occurred 
and the loss of plasma membrane integrity is observed. For this experiments, the 
Annexin-V FLUOS staining kit (Roche, USA) was used to detect the apoptosis of the 
NSC-34 cells. Briefly, after the various treatments, the NSC-34 cells were washed 
with PBS for two times and then incubated with the labeling solution containing 
Annexin-V-FITC and PI for 10 minutes in the dark at room temperature. The NSC-34 
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cells were washed with ice cold PBS for twice, mounted using fluorescent mounting 
medium containing DAPI (Vector, UK) and visualized using a confocal microscope.    
 
2.7. Induction of aggregates in NSC-34 neurons 
To evaluate the effects of BVCM on the formation of aggregate NSC-34 neurons, we 
first used the 2,5-hexanedione (2,5-HD) to induce the aggregates in the NSC-34 
neurons. After  the NSC-34 neurons were seeded into poly-D-lysine and collagen 
coated coverslips in the 6-well plate in DMEM/F12 (Invitrogen, USA) at 
5x105cells/well for 24 hours, the NSC-34 neurons were treated with 2.8, 4.2, 5.6, and 
7mM 2,5-HD (Sigma, USA) respectively for 1, 3, 5, or 7 days in DMEM/F12 without 
serum. MTS assay was employed to determine the NSC-34 cell viability. 
Immunocytochemistry was employed to detect the formation of aggregates.  
 
2.8. Detection of aggregates by immunohistochemistry 
Materials: 
PBS: 
     Na2HPO4 (H2O)7                                                    13.3g 
     NaCl                                                                          8.5g 
Distilled water to make up to                                1000ml 
The solution was adjusted to pH 7.4 with 1N HCl. 
 
PB: 
     Na2HPO4 (anhydrous)                                          10.9 g 
     NaH2PO4 (anhydrous)                                             3.2 g 
Distilled water                                                    1000 ml 
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Mix and adjust the pH to 7.0 by either 1N HCl or 1N NaOH. 
 
4% PF:  
    Paraformaldehyde                                                    40g 
    0.1M PB                                                              1000ml 
Dissolve the PF by heat to 80°C and cool to room temperature before use. 
 
PBS-TX: 
    TritonX-100           1ml 
    PBS                                              1000ml 
 
The formation of aggregates was visualized by immunohistochemistry under a 
confocal microscope. Briefly, the cells were washed with PBS for 5 minutes, then 
fixed in 4% PF for 30 minutes and permeabilized with PBS-TX for 10 minutes. After 
blocking in normal sheep serum for 1 hour, the cells on coverslips were incubated 
with polyclonal rabbit anti-neurofilament heavy chain LSP antibody (NFH-LSP, 
1:200, Chemicon, CA) overnight at 4℃, and then with Cy3-conjuncted sheep anti-
rabbit IgG (1:200, Sigma, USA) and FITC-labeled phalloidin (for actin, 1:200, Sigma, 
USA) in PBS for 1 hour. Finally, the coverslips were mounted using fluorescent 
mounting medium containing DAPI (Vector, UK). All the fluorescent figures were 
taken using Olympus Fluoview FV1000 Laser Scanning Confocal Microscope. The 
numbers of aggregate-bearing NSC-34 neurons were counted and the percentages of 
aggregate-bearing NSC-34 cells were calculated. 
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2.9 Effects of 1μg/ml LPS-BVCM on the formation of aggregates in NSC-34 
neurons 
The NSC-34 cells were collected from 75-cm2 flask and washed with DMEM/F12 
twice before seeding into poly-D-lysine and collagen coated coverslips in the 6-well 
plate in DMEM/F12 (Invitrogen, USA) at 5x105cells/well for 24 hours. The effects of 
low concentrations of the 1μg/ml LPS-BVCM on the formation of aggregates were 
then studied. The 5% and 10% of 1μg/ml LPS-BVCM were applied to the healthy 
NSC-34 cells together with 7mM 2,5-HD in DMEM/F12. The 7mM 2,5-HD treated 
NSC-34 cells without the LPS-BVCM served as the control. The 
immunocytochemistry mentioned above was employed to detect the formation of 
aggregates. The aggregates were visualized using a confocal microscope (Olympus 
FV1000). The numbers of aggregate-bearing NSC-34 cells and total numbers of NSC-
34 were counted at day 1, 3, 5 and 7 at random selected views. The percentages of 
aggregate-bearing neurons were calculated. 
 
2.10 Neurite growth assay 
The NSC-34 cells were collected from 75-cm2 flask and washed with DMEM/F12 
twice before seeding into poly-D-lysine and collagen coated coverslips in the 6-well 
plate in DMEM/F12 (Invitrogen, USA) at 5x105cells/well for 24 hours. Then the 
NSC-34 neurons were treated by 25%, 50% and 75% of 1μg/ml LPS-BVCM in 
DMEM/F12 for 36 hours. The non-treated NSC-34 neurons in DMEM/F12 cultured 
for 36 hours served as control. After the treatment, the NSC-34 neurons were washed 
with PBS (2 times) and fixed in chilled 100% methanol for 20 minutes, stained with 
neurite stain solution purchased from Chemicon (NS200, Chemicon, USA) for 15 
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minutes at room temperature, and finally washed in excess PBS. The number of NSC-
34 neurons with processes was counted and the percentage calculated. 
 
2.11 Statistical analysis 
All the experiments were repeated in triplicate for statistical purpose, and where 
appropriate the data were presented as mean and standard deviation (SD). Statistical 
analyses were performed by one-way or two-way ANOVA test. The level of 
significance was set at p<0.05. 
 
3. Results 
3.1 Quantification of TNF-α, IL-1β and IL-6 in LPS-BVCM by ELISA 
The concentrations of TNF-α, IL-1β and IL-6 in the LPS-BVCM were measured 
using the ELISA kits. The exposure of BV-2 cells to different concentrations of LPS 
for different time intervals increased the concentration of TNF-α, IL-1β and IL-6 in 
the serum free culture media in a concentration- and time-dependent pattern. The 
significant upregulation in release of TNF-α (Fig.1A) or IL-6 (Fig.1B) was detected 
at 4 hours after 500 or 1000 ng/ml LPS treatment and reached the highest 
concentration (6026.92±630.98 pg/ml for TNF-α or 3050.56±230.01pg/ml for IL-6) 
at 24 hours after treatment with 1μg/ml LPS whereas the concentration of IL-1β was 
significantly increased at 8 hours and reached to the highest (13418.47±1190.01pg/ml) 
at 24 hours after treatment with 1μg/ml LPS for 24 hours (Fig.1C). It is worthy to note 
that 500ng/ml and 1μg/ml LPS treatment almost had the same stimulating effects on 




Figure 1. Quantification of TNF-α, IL-1β and IL-6 in LPS-BVCM by ELISA  
The concentrations of TNF-α, IL-1β and IL-6 in the LPS-BVCM were measured 
using the ELISA kits according to the manufacturer’s instruction. The exposure of 
BV-2 cells to different concentrations of LPS for different periods increases the 
concentration of TNF-α, IL-1β and IL-6 in the serum free culture media. The 
increase of the concentration of   TNF-α, IL-1β and IL-6 shows a concentration- 
and time-dependent pattern. The concentration of TNF-α reaches the highest 
concentration of 6026.92±630.98 pg/ml after treated with 1μg/ml LPS for 24 hours 
(A). The concentration of IL-6 reaches the highest concentration of 
3050.56±230.01pg/ml after treatment with 1μg/ml LPS for 24 hours (1B) whereas 
the concentration of IL-1β reaches the highest of 13418.47±1190.01pg/ml after 
treatment with 1μg/ml LPS for 24 hours (C). From the figure, 500ng/ml and 
1μg/ml LPS almost have the same stimulation effects on the productions of TNF-α 
and IL-6.  
 
3.2 Effects of LPS-BVCM on the NSC-34 cell viability 
No cytotoxic effects of LPS-BVCM on NSC-34 neurons were observed after the BV-
2 microglial cells were stimulated with 5, 10, 100, or 500ng/ml LPS for 36 hours; 
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however, higher NSC-34 viabilities (more than 100%) over the DMEM/F12 control 
have eventually indicated neurotrophic effects from the 5, 10, 100, or 500ng/ml LPS-
BVCM (Fig.2). More interestingly, after 1μg/ml LPS stimulation the LPS-BVMC 
presented opposite effects on NSC-34 viability. After 36-hour treatment, lower 
concentrations (i.e. 10%, 25% and 50% of 1μg/ml LPS-BVCM in DMEM/F12) have 
resulted in significant increases in NSC-34 cell viabilities. The viabilities at these 
concentrations exceeded 100% and reached the highest, 170%, when treated with 
25% of 1μg/ml LPS-BVCM in DMEM/F12.  However, at the higher concentrations 
(i.e. 75% and 100% 1μg/ml LPS-BVCM in DMEM/F12), the LPS-BVCM has led to 
significant decreases in NSC-34 cell viabilities.  The lowest NSC-34 cell viability 
observed was 45.9% compared to the untreated control after being treated with 100% 
1μg/ml LPS-BVCM for 36 hours.  
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Figure 2. Effects of LPS-BVCM on the NSC-34 cell viabilities 
No cytotoxic effects of BV-2 conditioned media on NSC-34 neurons was observed 
after the BV-2 microglia were stimulated with 5, 10, 100, or 500 ng/ml LPS; 
however, higher NSC-34 viabilities (more than 100%) over the DMEM/F12 
control have eventually indicated neurotrophic effects from the 5, 10, 100, or 500 
ng/ml LPS-BVCM. More interestingly, after 1μg/ml LPS stimulation, the LPS-
BVMC presents microglial dual effects on NSC-34 viability. After 36-hour 
treatment, lower concentrations (i.e. 10%, 25% and 50% of 1μg/ml LPS-BVCM in 
DMEM/F12) have been found to result in significant increases in NSC-34 cell 
viabilities. The viabilities at these concentrations exceed 100% and reach the 
highest, 170%, when treated with 25% of 1μg/ml LPS-BVCM in DMEM/F12.  
However, at the higher concentrations (i.e. 75% and 100% 1μg/ml LPS-BVCM in 
DMEM/F12), the LPS-BVCM can lead to significant decreases in NSC-34 cell 
viabilities.  The lowest NSC-34 cell viability observed is 45.9% compared to the 





In order to investigate if the LPS has toxic effects on the NSC-34 cells, LPS at various 
concentrations was applied to NSC-34 cells for 36 hours, the results indicated that 
LPS alone did not change the viability of NSC-34 cells cultured in DMEM/F12 and 
there was no statistically significant difference between different groups (Fig. 3) 
Figure 3. Effects of LPS on NSC-34 neuron viabilities  
NSC-34 cells were treated with 100, 250, 500, 750ng/ml and 1μg/ml LPS in 
DMEM/F12 for 36 hours. The viabilities were measured by MTS assay. NSC-34 
cells cultured in DMEM/F12 for 36 hours served as control. There is no 
significant difference in the viabilities of NSC-34 cells between different groups. 
 
 
3.3. PS externalization in NSC-34 cells  
After it has been confirmed that the higher concentrations of 1μg/ml LPS-BVCM 
could cause the death of NSC-34 cells, the Annexin-V assay was employed to identify 
which way the NSC-34 cells died when induced by microglial toxicity. After 
treatment with 100% 1μg/ml LPS-BVCM for 36 hours, the NSC-34 cells showed an 
Annexin-V positive and PI negative (Annexin-V+/PI-) staining pattern (Fig. 4) which 
indicated the externalization of PS, i.e., the translocation of the membrane 
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phospholipid phosphatidylserine (PS) from the inner to the outer leaflet of the plasma 
membrane―an early sign of apoptosis.  
A B 
Figure 4. PS externalization in NSC-34 cells  
The phosphatidylserine (PS) externalization (green in color), an early apoptotic 
marker, was visualized using Annexin-V/PI staining. The NSC-34 cells were 
treated with 1μg/ml LPS-BVCM for 36 hours. The positive staining can be 
observed on the surface of cells (arrows) which may be in the early stage of the 
apoptosis. A few densely stained smaller structures may represent fragmentation 
of the apoptotic cells (arrowhead). Hardly any PI staining (red in color) can be 
observed indicating that the most cells observed were in the early stage of 
apoptosis. A: Annexin-V-FITC; B: Bright Filed View + Annexin-V-FITC. 
(Bar=50μm) 
 
3.4. The effects of 2,5-HD on NSC-34 neurons 
3.4.1. The effects of 2,5-HD on aggregate formation in NSC-34 cells 
After 24 hours in serum-free DMEM/F12 media, round NSC-34 cells differentiated 
into neurons with various numbers of processes and then the cells were treated with 
2.8, 4.2, 5.6 or 7.0mM 2,5-HD up to 7days. 2,5-HD induced protein aggregates (Fig.5) 
in differentiated NSC-34 neurons in a time- and concentration-dependant manner 
(Fig.6). At 7 days treatment with 7.0mM 2,5-HD, neurofilament heavy chain (NFH) 
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positive aggregates  were present in the distal part of the processes in almost 70% of 
the NSC-34 neurons indicated by Cy3-conjunted anti-NFH immunostaining. However, 
there was no obvious difference in the actin filaments between the 2,5-HD treated 
cells and the control by FITC-Phalloidin staining. Following the reduction in the 
concentration of the 2,5-HD or treatment time, the percentage of the aggregate-
bearing NSC-34 neurons also decreased. Exposure of the cells to 2.8mM 2,5-HD for 7 
days induced aggregation only in around 7% of the cells, while 4.2mM and 5.6mM 




Figure 5. Visulization of aggregates by immunocytochemistry 
NSC-34 neurons were treated with 7mM 2,5-HD for 7 days and then triply stained 
with DAPI (blue for nucleus), Phalloidin-FITC (green for actin) and antiserum to 
NFH revealed by Cy3 fluorescence (red for NFH). Note that the round aggregates 
(arrows) are mostly formed at the distal portion of the processes when treated with 
2,5-HD (A) but absent in the normal control (B) although the growth cone 
(arrowhead) can be observed as a enlargement at the end of the processes. 
(Bar=20μm) 
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Figure 6. The effects 2,5-HD on the aggregate formation in NSC-34 neurons  
NSC-34 neurons were treated with 2.8, 4.2, 5.6 or 7.0 mM 2,5-HD for 1, 3, 5, or 7 
days. After the aggregates were visualized by NFH immunocytochemistry, the 
numbers of aggregate-bearing NSC-34 neurons were counted. The formation of 
NFH aggregates in the NSC-34 neurons after the 2,5-HD treatment presents a 
time- and concentration-dependent pattern (**: p<0.01). 
 
 
3.4.2. The effects of 2,5-HD on the viability of NSC-34 cells 
After the treatment of 2,5-HD, the viability of NSC-34 neurons were investigated 
using MTS assay. The concentration- and time-response experiments have indicated 
that treatments with 2.8, 4.2, 5.6 and 7mM 2,5-HD for 1, 3, 5, and 7 days did not 
significantly vary the viability of the NSC-34 neurons. For example, at the day 7, the 
viability of the 2.8, 4.2, 5.6 and 7mM 2,5-HD treated cells were 92.8%, 97.3%, 92.0%, 
and 85.9% respectively compared to the control. Furthermore, the viabilities treated 
by 7mM for 1, 3, 5, and 7 days were 87.7%, 89.9%, 91.4% and 85.9% respectively 
(Fig.7). There was no statistically significant difference between different groups. 
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Figure 7. Effects of 2,5-HD on NSC-34 neuron viabilities  
NSC-34 neurons were exposed to 2.8, 4.2, 5.6 or 7 mM 2.5-HD in DMEM/F12 for 
1, 3, 5, or 7 days respectively before the viabilities were investigated by MTS 
assay. No significant differences of the viabilities among the NSC-34 neurons 
between different groups are observed  using MTS assay. 
 
 
3.5. Effects of LPS-BVCM on the formation of aggregates in NSC-34 cells 
The dual effects, neuroprotection/neurotrophy and neurodestruction/neurotoxicity, of 
1μg/ml LPS-BVCM on the viability of NSC-34 cells have been observed. It was 
further investigated whether the lower concentrations of 1μg/ml LPS-BVCM could 
have any effects on the formation of aggregates induced by 2,5-HD in NSC-34 
neurons. The results showed that when the NSC-34 neurons were treated with 7mM 
2,5-HD and 10% or 15% of 1μg/ml LPS-BVCM together, the percentage of 
aggregate-bearing NSC-34 neurons was dramatically decreased, compared to that in 
the control after the administration of 7mM 2,5-HD only (Fig.8). At day 7, there were 
only 8.8% and 6.2% aggregate-bearing cells when treated with 2,5-HD together with 
5% and 10% 1μg/ml LPS-BVCM in DMEM/F12 respectively but 70% of the cells 
formed aggregates when treated with 2,5-HD alone. 
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Figure 8. The effects of 10% and 15% of LPS-BVCM on the 2,5-HD-induced 
aggregates formation in NSC-34 neurons  
The NSC-34 cells were treated with 7 mM 2,5-HD alone or treated with 7 mM 2,5-
HD together with 10% or 15% LPS-BVCM in DMEM/F12 for 7 days. The 
aggregates were visualized by immunocytochemistry, the numbers of aggregate-
bearing NSC-34 cells were counted, and the percentages were calculated. While a 
large number of aggregates has formed in the 2,5-HD treated cells on day 5 and 7, 
the addition of 10 or 15% 1μg/ml LPS-BVCM can interrupt the effects of 2,5-HD 
on the NSC-34 neurons and prevent the NFH accumulation in the processes of the 
cells (*** p<0.001). 
 
 
3.6. Effects of LPS-BVCM on the outgrowth of processes of NSC-34 neurons 
The dual effects of 1μg/ml LPS-BVCM on the outgrowth of processes of NSC-34 
neurons were also investigated. After treatment with, 25%, 50% and 75% of 1μg/ml 
LPS-BVCM in DMEM/F12 for 12 hours, the NSC-34 neurons were stained with the 
neurite staining buffer (Fig.9) and the cells with long processes were counted. The 
results showed that the higher concentration of 1μg/ml LPS-BVCM could inhibit the 
outgrowth of processes of NSC-34 neurons. When treated with 25% and 50% LPS-
BVCM for 24 hours, the percentage of NSC-34 neurons with processes were 32% and 
38% respectively whereas 30% for non-treated control, but when treated with 75% 
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1μg/ml LPS-BVCM, the percentage of NSC-34 neurons with processes dropped to 
around 20% (Fig.10). 
A B
DC 
Figure 9. Outgrowth of the processes of NSC-34 neurons  
Under the serum free condition, NSC-34 neurons started to differentiate and their 
processes began to grow and extend. The NSC-34 neurons were cultured in 
different concentrations (25% (B), 50% (C), and 75% (D)) of 1μg/ml LPS-BVCM 
in DMEM/F12 for 36 hours. NSC-34 neurons cultured in DMEM/F12 (A) for 36 
hours served as control. For cell counting, the cells with long and obvious 
processes (arrow) and the cells with very short or without processes (arrowhead) 
were identified. (Bar=100μm). 
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Figure 10. The percentage of the NSC-34 neurons with processes  
When treated with lower concentrations (25% or 50%) of 1μg/ml LPS-BVCM in 
DMEM/F12, the percentages of NSC-34 neurons with long and obvious processes 
increase. However, the percentage of the NSC-34 neurons with processes is 
significantly reduced after the cells are treated with a higher concentration (75%) 
of 1μg/ml LPS-BVCM (**p<0.01).  
 
 
4. Discussion  
It has been widely believed that microglia possess dual functions, but it is still unclear 
when and how microglia exert its neuroprotective/neurotrophic or 
neurodestructive/neurotoxic function. In this present study, the dual effects of BV-2 
microglial cells on NSC-34 neurons were demonstrated to be related with the 
concentration of LPS-BVCM as well as the dosage of LPS applied to BV-2 cells. 
 
4.1 The nature of microglial function could be determined by the amount of LPS 
applied to microglia 
 BV-2 microglial cells were activated by different concentrations of LPS. The MTS 
assay showed that after BV-2 microglia were stimulated with 5, 10, 100, or 500ng/ml 
LPS, beneficial effects but not cytotoxic effects have been laid on NSC-34 cells as all 
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NSC-34 cell viabilities measured exceeded the control. The neuronal cell death could 
be induced by 1μg/ml LPS-stimulated microglia in the current setting. This indicates 
that intensity of a stimulator to microglia may be important in the determination of the 
nature of microglial function.  
 
4.2 The concentration of conditioned medium from 1μg/ml LPS-stimulated 
microglia present opposing functions: neuroprotection or neurotoxicity 
However, after 1μg/ml LPS stimulation, the BVMC presented microglial dual effects 
on NSC-34 cell viability and resulted in significant increases in either survival or 
death of NSC-34 cells under given conditions. At 36 hours, lower concentrations (e.g. 
10%, 25% and 50%) of 1μg/ml LPS-BVCM in DMEM/F12 have been found to result 
in significant increases in NSC-34 cell viabilities. But, at the higher concentrations 
(e.g. 75% and 100%) of 1μg/ml LPS-BVCM in DMEM/F12, the LPS-BVCM has led 
to significant decreases in NSC-34 cell viabilities. Cell death via apoptosis was 
observed only in the groups applied with higher concentrations of 1μg/ml LPS-
BVCM (75% and 100%). The dosage of LPS applied to BV-2 cells and the 
concentration of LPS-BVCM may possibly represent the intensity of stimuli and the 
degree of microglial activation in vivo. The connection between microglial dual 
effects and its activation is the equilibrium of all the factors in the LPS-activated 
microglial conditioned medium but not any specific factors. This view would avoid 
the limitation of ignoring the network and cross talk of all kinds of bio-factors that 




4.3 Lower concentration of LPS-activated microglial conditioned medium can 
prevent the formation of protein aggregation in neurons from 2,5-HD toxicity 
The protective function by the lower concentration of LPS-BVCM was also evident in 
the 2,5-HD toxic experimental setting. In the present study, 2,5-HD has been 
confirmed to induce accumulations of neurofilaments in the processes of 
differentiated NSC-34 neurons, which was similar to the effects of 2,5-HD in vivo that 
it could induce accumulations of neurofilaments in the axons but not in the neuronal 
perikarya in humans as well as in experimental animals (LoPachin et al., 2005). This 
disturbing effect of 2,5-HD on neurofilaments was further confirmed in a 
concentration- and time-dependant manner without significantly altering the viability 
of the NSC-34 cells even after these same cells were treated by 7mM 2,5-HD for 7 
days. After the application of lower concentrations of 1μg/ml LPS-BVCM together 
with 2,5-HD, the percentage of aggregate-bearing NSC-34 neurons dramatically 
decreased compared to that of the control, suggesting that some factors from activated 
microglia could somehow protect the NSC-34 cells by preventing the formation of 
2,5-HD induced neurofilament aggregation in NSC-34 neuronal processes. 
 
4.4 Lower concentration of LPS-activated microglial conditioned medium can 
promote the outgrowth of the processes of neurons 
The microglial dual roles over outgrowth of processes of NSC-34 neurons have also 
been displayed in a concentration dependent manner: Low concentrations (25% and 
50%) of 1μg/ml LPS-BVCM showed a promotional effect on the outgrowth of the 
processes of NSC-34 neurons while higher concentration (75%) of 1μg/ml LPS-
BVCM significantly inhibited their outgrowth. 
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4.5 Mechanism of microglial dual effects: Equilibrium in functions of various 
biofactors released from activated microglia is the key in microglial dual 
function   
4.5.1 Microglia could produce multi-factors with opposing functions 
From the literature review (Kim and de, 2005;Kreutzberg, 1996) and microarray 
analysis (Thomas et al., 2006), it have been shown that activated microglia could 
secrete a large scale of factors including cytokines, chemokines, and enzymes to the 
regional environment upon stimulation. These factors possess opposing functions as 
reviewed in the Introduction. Therefore, it seems to be improper to judge microglial 
functions by only assessing a few specific microglial factors while ignoring the others.  
 
4.5.2 The onset time and amount of upregulation of those factors may vary 
significantly 
Based on microarray data, the upregulation or downregulation of LPS-activated 
microglial factors ranged from two to thousand folds suggesting that concentrations of 
corresponding factors may vary accordingly. The detection of a few selected 
cytokines in the LPS-activated microglial supernatant has confirmed that not only the 
onset time for significant upregulation in cytokine expressions (4 hours for TNF-α 
and IL-6 but 8 hours for IL-1β) was different but also the concentrations of the 
cytokines varied significantly (6026.92±630.98pg/ml for TNF-α and 
3050.56±230.01pg/ml for IL-6 but 13418.47±1190.01pg/ml for IL-1β). This suggests 
that some neurotoxic factors might become negligible after the activated microglial 
supernatant has been further diluted and resulted in a dramatic shift of microglial 
function from destruction/toxicity to protection/trophicity or vise versa. This provides 
a reasonable support for hypothesis proposed in this study that the balance between 
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co- and counter-effects of various microglial factors might determine the 
protective/trophic or destructive/toxic role of microglia in a given disease or injury 
circumstance. The findings in the present study might shed some lights on this issue 
and the key discovery is that the nature of microglial function on neuronal cells can be 
configured by the concentration of LPS-BVCM.  
 
4.5.3 Explanation of some phenomena in vivo using the hypothesis on microglial 
dual functions 
In many injury and disease models, microglial activation has gradually increased from 
mild to intense. For instance, the expression of CR3, a most commonly used 
microglial marker, has been reported to be only slightly upregulated on day 1 but 
became dramatically upregulated on day 5 in the vicinity of axotomized motor 
neurons (He et al., 1997). In concert with the current findings, similar time-dependant 
increase can also be noted in the expressions of many cytokines from activated 
microglia (Eriksson et al., 2000;Johnson et al., 2006). In most aggregate-related 
neurodegenerative diseases, post-mortem analysis found the clustering of activated 
microglia around the diseased region (Dickson et al., 1993;McGeer et al., 1988). 
Although the change in microglial numbers has been claimed to be as the result of 
microglial proliferation and migration, the increase in the number of activated 
microglia in the disease foci may result in increases in both the concentration of 
factors released from activated microglia and the formation of concentration gradient 
of microglial released factors. Therefore, the reported dual function of microglia may 
be related to the spatial distribution and degree of activation of microglia in the 
injured/diseased region in the CNS. Based on the present results, the present author 
hypothesizes that in an earlier reaction stage, microglia in mild activation may be 
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trying to protect the diseased neurons. If the illness causative effects on neurons have 
not been overcome, then at a later stage, more microglia become activated,  
accompanied with proliferation and migration to the center of the disease foci to exert 
their destructive functions. 
 
In this chapter, the results indicated that microglial toxicity can result in the apoptosis 
in NSC-34 neurons in vitro. In the next chapter, the author will investigate the 
function of Bcl-2 family members during the apoptosis induced by the high 











































In previous chapter, the results have indicated that microglial toxicity can result in the 
apoptosis in NSC-34 cells in vitro. In order to understand the molecular mechanisms 
involved in microglial dual functions, the function of Bcl-2 family members during 




Neuronal death is a key feature of both development of the nervous system and 
neuropathogenesis of neurological diseases. Many studies have shown that apoptosis 
is involved in the neuronal death. Some studies reported that apoptotic cells and DNA 
fragmentation were seen in the brain tissue of PD patients by postmortem analysis 
(Anglade et al., 1997;Mochizuki et al., 1996).  Other than PD, inappropriate apoptosis 
has also been implicated in many other human diseases such as AD, Huntington’s 
disease (HD), ischemic damage, autoimmune disorders, and several forms of cancers 
(Nicholson, 1996;Thompson, 1995).  Other studies also showed that apoptotic cells 
could be found in various neurons including retinal ganglion cells (Quigley et al., 
1995;Rabacchi et al., 1994), spinal motor neurons (Gu et al., 1997), sensory neurons 
(Groves et al., 1997), and facial motor neurons (de and Dubois-Dauphin, 1996) in 
neonatal and adult rodents after axotomy of the optic, sciatic and facial nerves, 
respectively.   
 
Other than the in vivo evidence of the involvement of apoptosis in neuronal loss, some 
in vitro studies also showed that apoptosis is responsible to neuronal death caused by 
different toxicities. For examples, Robertson et al. reported that the TNF-α could 
induced the apoptosis in the neurons exhibiting peripherin aggregates (Robertson et 
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al., 2001). Exposing neural cells to carbon monoxide could induce the hypoxia 
independent apoptosis in vitro (Tofighi et al., 2006). Furthermore, the deprivation of 
potassium or serum could cause the apoptosis in granule neurons in vitro (Perez-
Capote et al., 2005).  All the evidence has indicated that apoptosis plays an important 
role during the neuron death both in vivo and in vitro.  
 
However, the causes for death of neurons are different, and the mechanisms 
responsible for apoptosis of neurons also vary. Among all the factors that could be 
involved in the apoptosis, Bcl-2 family members seemed to be most interesting and 
have been widely studied. It was reported that the expression of Bim increased during 
the AD and it was required for beta-amyloid-induced neuronal apoptosis (Biswas et 
al., 2007). Moreover, full length Bid was reported to be able to induce apoptosis in the 
cultured rat hippocampal neurons (Konig et al., 2007). It has also been shown that 
deficiency in Bad or Bim exhibited a reduced activated-caspases-3 activity in the 
brain after hypoxia-ischemia suggesting the possible involvement of Bad/Bim in the 
activation of apoptosis executor-caspase-3 (Ness et al., 2006). Other than these pro-
apoptotic members, the anti-apoptotic Bcl-2 family members were also reported to 
play important roles during neuronal apoptosis. Overexpression of Bcl-xL could 
increase the percentage of motoneuron survival after axotomy (Parsadanian et al., 
1998). Bcl-2 could prevent motoneuron death after ischema and inhibited cytochrome 
c leakage from the mitochondria (Zhao et al., 2003). All the evidence indicates that 
different Bcl-2 family members play different regulatory roles during neuronal 
apoptosis under different circumstances.  
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Diva is a newly identified Bcl-2 family member. It is structurally similar to the anti-
apoptotic Bcl-2, Bcl-xL, Bcl-w and Mcl-1. Diva contains all 4 types of BH domains 
and one TM (transmembrane) domain at its c-terminal which indicates that Diva 
could locate onto the inner cellular membrane by this TM domain.  Furthermore, from 
previous studies, both anti-apoptotic and pro-apoptotic functions of Diva have been 
reported (Inohara et al., 1998;Ke et al., 2001;Naumann et al., 2001;Song et al., 1999). 
Although it is possible that Diva may play different roles under different 
circumstances, the role of Diva in neurons in response to microglial cytotoxicity 
remains unclear. In the previous chapter, it has been shown that the high 
concentrations of LPS-BVCM could induce apoptosis in the NSC-34 cells in vitro. In 
this chapter, the possibility of involvement of Diva during the LPS-BVCM-induced 
cytotoxicity has been investigated.  
 
2. Materials and methods 
2.1. Tissue cell culture 
2.1.1. NSC-34 cell line 
Please refer to page 31 for details. 
 
2.1.2. BV2 cell line 
Please refer to page 32 for details. 
 
2.1.3. Maintenance of NSC-34 and BV2 cell line 




2.2. Activation of BV-2 cells by lipopolysaccharide (LPS) 
Please refer to page 32 for details. 
 
2.3. Treatment of NSC-34 cells by LPS-BVCM 
The NSC-34 cells were collected from 75-cm2 flask and washed with DMEM/F12 
twice before seeding into poly-D-lysine and collagen coated coverslips in the 6-well 
plate in DMEM/F12 (Invitrogen, USA) at 5x105cells/well.  Twenty-four hours after 
the seeding, 25% and 75% of LPS-BVCM in DMEM/F12 were added into the NSC-
34 cells for 36 hours. NSC-34 cells cultured in 100% DMEM/F12 for 36 hours served 
as the control.  
 
2.4. Real-Time polymerase chain reaction (Real-Time PCR) 
2.4.1. RNA isolation 
After 36 hour treatment by LPS-BVCM, the NSC-34 cells were collected by 
centrifuging at 1500rpm for 5 minutes, and total RNA was isolated from the cells in 
each well of a 6-well plate using the RNeasy Mini kit according to the manufacturer’s 
protocol. Briefly, after washing with PBS for two times, the cell pellets were lysed in 
350μl of Buffer RLT (provided with the kit, containing a highly denaturing 
guanidinium isothiocyanate which immediately inactivates RNase). After the lysate 
was passed through 22G needle for ten times, 350µl of 70% ethanol was then added 
to the cleared lysate and mixed well to provide appropriate binding conditions. Then 
the samples were applied to an RNeasy mini spin column (silica-gel membrane, 
maximum binding capacity is 100µg of RNA longer than 200 bases), spun for 15 
seconds at 10,000g and the flow through was discarded. During this step, the total 
RNA binds to the membrane. The RNA bound to the membrane was washed with 
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buffer RW1 and RPE (supplied in the kit) sequentially. High-quality RNA was then 
eluted in 30µl of RNase free water. The concentration and purity of the extracted 
RNA were evaluated by spectrophotometric absorbance readings at 260nm and 
280nm (Eppendorf Biophotometer, USA). 
 
2.4.2. First-strand cDNA synthesis using total RNA as template 
After the total RNA was extracted from the sample, 2µg of RNA of each sample were 
used to synthesize the first strand cDNA by using SuperScriptIII First-Strand 
Synthesis System for RT-PCR (Invitrogen, USA) following the manufacturer’s 
protocol. Briefly, 2µg total RNA were mixed with 1µl 10mM dNTP and 1µl 
Oligo(dT)21 primer and the final volume was topped up to 10µl by DEPC-treated 
water and incubated at 65°C for 5 minutes. After the incubation at 65°C, the tubes 
were allowed to cool down on ice for 1 minute. At the same time, the reaction mixture 
including 2µl 10X RT buffer, 4µl 25mM MgCl2 buffer, 2µl 0.1M DTT, 1µl 
RNaseOUT RNase Inhibitor and 1µl SuperScrpitIII Reverse Transcriptase were 
prepared to reach the final volume of 10µl. The reaction mixture was mixed with the 
RNA/Primer and the reaction system was incubated at 50°C for 50 minutes then at 
80°C for 5°C to stop the reaction.  Finally, 1µl of RNaseH was added to each reaction 
system and incubated at 37°C for 20 minutes to remove the RNA. The synthesized 
first-strand cDNA was diluted 10 times, stored at -20°C and used as template for next 
step of real-time RTPCR. 
  
2.4.3. Real-Time PCR 
Real-time quantitative RTPCR is a new approach in PCR-technology. It is much 
faster and more reliable than other semi-quantitative PCR-techniques, such as 
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competitive PCR and picture-analysis after electrophoresis. The SYBR-Green method 
uses SYBR-Green I® as a fluorescent dye which only intercalates specifically with 
double-strand DNA (dsDNA) during the extension phase of the PCR. For 
quantification of the starting amount of template DNA, the threshold cycle (Ct) of 
each sample is calculated. Ct-value is proportional to the logarithm of initial template 
DNA concentration. An aliquot of 1µl of synthesized first-strand cDNA was added in 
the reaction mixture (10µl) containing LightCyclerTM-FastStart DNA Master SYBR 
Green I, 1µM of each primer, and 3mM MgCl2. The forward and reverse primers used 
are listed in the Table 1. After pre-incubation at 95°C for 10 minutes, PCR was 
performed with 45 cycles of denaturation at 95°C for 15 seconds, annealing at 
temperatures corresponding to the genes (see Table 1) and elongation at 72°C for 
different time due to the PCR products sizes. The level of specific mRNA was 
quantified, expressed as Ct, the cycle number at which the LightCycler System 
detected the upstroke of the exponential phase of PCR product accumulation, and 
normalized by the level of GAPDH expression in each individual sample.  
Table 1. Primers used for real-time RT-PCR 
Gene       Primer: Forward (FW)                              Product size   Anneal tem(°C)   Extension tem (°C)  
Name                    Reverse (RV)                                     (bp)                  /Sec                       /Sec 
Bcl-2         5’-AGGAGCAGGTGCCTACAAGA-3’                166                   60/10                       72/7 
                  5’-GCATTTTCCCACCACTGTCT-3’                                    
Bcl-xL       5’-TTCGGGATGGAGTAAACTGG-3’                 157                   60/10                       72/7 
                  5’-TGGATCCAAGGCTCTAGGTG-3’ 
Bcl-w        5’-GGACAAGTGCAGGATTGGAT-3’                 158                   60/10                       72/8 
                  5’-GTCCTCACTGATGCCCAGTT-3’ 
Mcl-1        5’-AGAAATGTGCTGCTGGCTTT-3’                  165                   60/10                       72/7 
                  5’-GCAGCTTCAAGTCCACCTTC-3’ 
Bax           5’-CCAACATTGCATGGTGCTAC-3’                  173                   60/10                       72/7 
                 5’-AGGAGTGTTGGGAACACAGG-3’ 
Bok           5’-ACATGGGGCAAGGTAGTGTC-3’                186                   60/10                       72/8 
                  5’-GCTGACCACCACACTTGAGGA-3’   
Bad           5’-AGGACTTATCAGCCGAAGCA-3’                 187                   60/10                       72/8 
                  5’-GCTCAAACTCTGGGATCTGG-3’ 
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 Blk            5’-GAAGGAGCCTGTGAGAGACG-3’                229                   60/10                       72/10 
                  5’-GTTTTCCCTGAGGTTGGTGA-3’ 
Bid            5’-CTCTGCGTTCAGCTTGAGTG-3’                  206                    60/10                       72/9 
                  5’-CAGAAGCCCACCTACATGGT-3’ 
BimL         5’-CAACACAAACCCCAAGTCCT-3’                244                    60/10                       72/10 
                  5’-CATTTGCAAACACCCTCCTT-3’ 
Diva          5’-TGAGGAAGTCCTCCAGCCTA-3’                 240                   60/10                       72/10 
                  5’-GCAGCTCAAGAACCCAGAAC-3’ 
GAPDH    5’- AACTTTGGCATTGTGGAAGG-3’                223                   60/10                       72/9 
                  5’- ACACATTGGGGGTAGGAACA-3’ 
 
2.5. Detection of real-time RT-PCR products specificities 
The specificities of the real-time RTPCR products were investigated by 
electrophoresis in 1.5% agarose gel. Briefly, 1.5g agarose were disolved by heating in 
the TAE buffer (0.04M Tris-base, 0.001M EDTA, Glacial acetic acid, pH7.8). 
Ethidium bromide (EB) was added into the gel. The gel was cooled and poured onto a 
gel tray and allowed to solidify. Ten micro-liter of each RT-PCR product was loaded 
in each lane of the gel and electrophoresed at 80V for 60 minutes in TAE buffer along 
with 650ng of 100bp DNA ladder (Promega). The bands were visualized in the Chemi 
Genius2 Bio Imaging System (SynGENE, UK) and captured using GeneSnap 
Software (SynGENE, UK). The 100bp DNA ladder was used to determine the size of 
the amplified DNA from 100-1500bp. 
 
2.6. Overexpression of Diva in NSC-34 cells 
In order to confirm the anti- or pro-apoptotic function of Diva, the Diva was 
overexpressed in NSC-34 cells by constructing a mammalian expression plasmid. The 
open reading frame (ORF) of Diva has been cloned into the mammalian expression 
plasmid pcDNA6/myc-His© (Invitrogen, USA) containing a human cytomegalovirus 
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immediate-early (CMV) promoter which is able to overproduce recombinant proteins 
with a myc and/or poly-His-tag in mammalian cell line. The map of the plasmid is 
shown in the following picture.  
 
 
2.6.1. Cloning of Diva ORF from NSC-34 cells by PCR 
Full-length ORF without the stop codon of Diva was cloned by PCR using the 
specific primers for Diva’s CDS (GeneBank Accession No.: AF067660) and the 
synthesized first-strand cDNA from the total RNA was used as the template. The 
sequences of the primers are shown in Table 2.  
Table 2 Sequences of PCR primer for Diva ORF 
Gene    Primers                                                                                       Product size (bp)    
Diva    FW: 5’-ATGGCCGACTCGCAGGAC-3’                                           576               
            RV: 5’-TAAACGTTTCCAGATAAAAAAGAT-3’                                    
 
In a sterile thin walled PCR tube, 2.5μl Mg2+free 10x buffer, 1.5μl Mg2+ buffer, 
0.25μl Taq polymerase (Promega, USA), 0.5μl 10mM dNTP, 1μl 5mM FW primer, 
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1μl 5mM RV primer, 1μl cDNA template, and 17.25μl H2O were added in order and 
mixed well. The PCR cycle condition was setup as follows:  
          First denature:                                                     94°C for 2 minutes 
          Then programmed amplification cycle:              94°C for 30 seconds,  
                                                                                      60°C for 30 seconds 
                                                                                      72°C for 1 minute 
                                                                                      45 cycles 
          End with an extension:                                       72°C for 5 minutes   
The specificity and size of the PCR product were examined by electrophoresis 
running on 1.5% agarose gel.  
 
2.6.2. Gel Extraction of PCR products 
The correct sized bands were cut out and extracted for sequencing to make sure that 
the sequence was 100% correct to the Diva ORF. The QiaGen Gel Extraction Kit 
(QiaGen, USA) was used for the extraction of band from agarose gel following the 
manufacturer’s instruction. Briefly, the correct sized bands from the agarose gel were 
cut with a clean scalpel and weighted in a colorless tube. Three volumes of buffer QG 
(supplied in the kit) to 1 volume of gel (100mg gel equals to 100μl) and incubated at 
50°C for 10 minutes. After the gel slice dissolved, one gel volume of isopropanol was 
added into the tube and mixed. To bind the DNA, the samples were added into the 
QIAquick columns (supplied in the kit) and centrifuged for 1 minute at 13000rpm. 
Flow-through was discarded and 750μl buffer PE (supplied in the kit) was added to 
the QIAquick column to wash the DNA by centrifuging at 13000rpm for 1 minute. 
Again the flow-through was discarded and the column was centrifuged one more time 
at 13000rpm for 1 minute to remove the residue PE buffer. Finally, the QIAquick 
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column was put into a clean 1.5ml microcentrifuge tube and the DNA was eluted 
using 50μl autoclaved distilled water by centrifuging for 1 minute at 13000rpm. The 
eluted DNA was sent for sequenceing to make sure it is identical to the ORF of Diva.  
 
2.6.3. Add restriction enzyme site to the ORF of Diva by PCR 
In order to insert the ORF of Diva into the pcDNA6/myc-His© plasmid, restriction 
enzyme (RE) sites were added to the two ends of the ORF of Diva by PCR using 
primers containing the RE sites. The ORF of Diva was used as template. The two 
restrictions enzyme were HindIII for 5’-end and XhoI for the 3’-end. The primers used 
are shown in Table 3: 
Table 3 The PCR primers with RE site 
   Primers with RE site                                                                        Product size (bp)    
   FW: 5’-ATTAAGCTTATTATGGCCGACTCGCAGGAC-3’                                      597                      
                         HindIII    
    RV: 5’-ATCTCGAGATAAACGTTTCCAGATAAAAAAGAT-3’   
                        XhoI                                  
 
In a sterile thin walled PCR tube, 2.5μl Mg2+free 10x buffer, 1.5μl Mg2+ buffer, 
0.25μl Taq polymerase (Promega, USA), 0.5μl 10mM dNTP, 1μl 5mM FW primer, 
1μl 5mM RV primer, 1μl Diva ORF template, and 17.25μl H2O were added in order 
and mixed well. The PCR cycle condition was setup as follows:  
          First denature:                                                     94°C for 2 minutes 
          Then programmed amplification cycle:              94°C for 30 seconds,  
                                                                                      60°C for 30 seconds 
                                                                                      72°C for 1 minute 
                                                                                      45 cycles 
          End with an extension:                                       72°C for 5 minutes   
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The PCR products were examined for size by electrophoresis in 1.5% agarose gel. 
The corrected DNA band was extracted by using QIAquick Gel extraction Kit as 
described in 2.6.2 in page 65 and was sent to sequence.  
 
2.6.4. Double digestion of Diva ORF with RE site and pcDNA6/myc-His© plasmid. 
The purified Diva ORF with RE site and pcDNA6/myc-His© plasmid were double-
digested by HindIII and XhoI (New England Biolabs, USA). Briefly, in a sterile thin 
walled PCR tube, 5μl 10x buffer, 0.5μl 100x BSA, 2000ng Diva OFR with RE site or 
pcDNA6/myc-His© plasmid, and 2U Hind III, 2U XhoI, were added and topped up to 
the final volumn of 50μl by water. The reaction mixtures were incubated at 37°C for 3 
hours and the digested DNA were running in 1.5% agarose gel and extracted using 
QIAquick Gel extraction Kit as described in 2.7.2.  
 
2.6.5. Insert Diva ORF into pcDNA6/myc-His© by ligation reaction. 
The digested Diva ORF and pcDNA6/myc-His plasmid were ligated using the DNA 
T4 ligase (Promega, USA). In a sterile thin walled PCR tube, added 100ng digested 
pcDNA6/myc-His©, 30ng digested Diva ORF with RE site, 1μl 10x buffer, 1u ligase, 
topped up to 10μl by water. The ligation reaction mixture was incubated at 16°C 
overnight.  
 
2.6.6. Transformation of DNA from ligation reaction into DH5α competent cells 
The plasmid with Diva ORF insertion was transformed into DH5α competent cells 
(Invitrogen, USA) for selection and upscaling. The competent cells were thawed on 
wet ice. 10μl of DNA from ligation reaction was mix with 50μl of competent cells and 
incubated on ice for 30 minutes. After heat-shock at 42°C for 45 seconds in a water 
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bath, the cells were placed on ice for 2 minutes. Then 500μl LB medium was added 
into the cells and the cells were shaken at 225rpm for 1 hour to be recovered. After 1 
hour of shaking, the cells were plated onto the LB plate containing 50μg/ml ampicillin 
and incubated at 37°C for 12-16 hours.   
 
2.6.7. Extraction of plasmid from transformed DH5α 
The single colony from the selective LB plate was picked up and inoculated in 5 ml 
LB medium containing 50μg/ml ampicillin for 8 h at 37°C with vigorous shaking at 
300rpm.  After 8 hour incubation, the 5ml of culture was transferred into 100ml LB 
medium containing the 50μg/ml ampicillin in a flask and incubated overnight at 
250rpm. The plasmid was extracted using QiaGen High Speed Midi Kit (QiaGen, 
USA) following the manufacturer’s instruction. Briefly, cells in 100ml LB medium 
were harvested by centrifuge at 6000g for 15 minutes at 4°C.  The bacterial pellet was 
resuspended in 6ml buffer P1 (supplied in the kit) and 6ml buffer P2 (supplied in the 
kit) were added, mixed thoroughly by vigorously inverting the sealed tube for 4 to 6 
times and incubated at room temperature for 5 minutes.  Then 6 ml of chilled buffer 
P3 (supplied in the kit) were added into the lysate and mixed immediately and 
thoroughly by vigorously inverting the tube for 4 to 6 times. The lysate was poured 
into the barreled QIAfilter Cartridge (supplied in the kit) and incubated at room 
temperature for 10 minutes. At the same time, the HiSpeed Midi Tip (supplied in the 
kit) was equilibrated by 4ml of buffer QBT (supplied in the kit) and was allowed to 
empty by gravity flow. After the HiSpeed Midi Tip was equilibrated, the lysate was 
filtered into the Tip from the QIAfilter Cartridge by inserting a plunger. The cleared 
lysate was allowed to enter the resin by gravity flow. The resin was then washed by 
20ml buffer QC (supplied in the kit) which was allowed to move through by gravity 
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flow. After the washing, the DNA was eluted from the HiSpeed Midi Tip by using 
15ml buffer QF (supplied in the kit), precipitated by adding 3.5ml isopropanal into the 
eluted DNA and incubated at room temperature for 5 minutes. The precipitated DNA 
was then transferred into a sterilized 20ml syringe and filtered through the 
QIAprecipitator (supplied in the kit) using constant pressure. Then the DNA in the 
QIAprecipitator was washed by 2ml 70% ethanol. Finally the DNA was eluted from 
the QIAprecipitator by 1.5ml sterilized water and sent to sequence. The concentration 
and purity of the extracted plasmid were evaluated by spectrophotometric absorbance 
readings at 260nm (Eppendorf Biophotometer, USA). The plasmid with correct 
inserted Diva ORF was named as pcDNA6-Diva. 
 
2.7. Transfection of pcDNA6-Diva into NSC-34 cells 
2.7.1. Optimization of conditions for transfection of pcDNA6-Diva into NSC-34 
For the transfection of overexpression plasmid pcDNA6-Diva into the NSC-34 cells, 
the lipofectamine2000 transfection reagent (Invitrogen, USA) was used. One day 
before the transfection, NSC-34 cells were seed into the 6-well plate in DMEM plus 
10% fetal bovine serum (FBS) without antibiotics.  The next day, for each sample of 
transfection, the transfection reagent and pcDNA6-Diva complex were prepared as 
follows and added into the NSC-34 cells:  
a. Dilute DNA in 50μl of Opti-MEM I Reduced Serum Medium (Invitrogen, 
USA), mixed gently. 
b. Dilute appropriate amount of Lipofectamine2000 transfection reagent in 50μl 
Opti-MEM I Medium and incubated for 5 minutes at room temperature.  
c. After the 5 minute incubation, the diluted DNA and Lipofectamine2000 reagent 
were combined together and incubated at room temperature for 20 minutes before 
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added into the cell culture. The cells were incubated at 37°C in a CO2 incubator 
for 48 hours and the expression of Diva was investigated by real-time RT PCR. 
 
To obtain the highest transfection efficiency and low non-specific effects, the 
transfection conditions were optimized by varying plasmid and Lipofectamine2000 
concentrations. The empty pcDNA6/myc-His plasmid was transfected into the NSC-
34 cells and served as the control. The concentration of plasmid and 
Lipofectamine2000 that have been tried in the current study are listed in Table 4. 










6-well plate 10cm2 4 2 
6-well plate 10cm2 4 4 
6-well plate 10cm2 4 10 
6-well plate 10cm2 4 20 
 
2.7.2. Treatment of transient transfected NSC-34 cells by LPS-BVCM 
In the prevous part in this chapter, the microglial cytotoxicity on NSC-34 cells was 
studied when the NSC-34 cells were cultured in the DMEM/F12 but not in the 
DMEM plus serum. So in order to be coincident with previous experiment, the 
transfection of pcDNA6-Diva were also carried out when the NSC-34 cells were 
cultured in the DMEM/F12 at the optimized conditions before treated with different 
concentrations of LPS-BVCM.  
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2.7.2.1. Transfect NSC-34 cells at optimized condition  
One day before the transfection, the NSC-34 cells were seeded in a 25-cm2 flask in 
DMEM plus 10% FBS. The next day, the NSC-34 cells were transfected with 
pcDNA6-Diva under the optimized condition. Empty pcDNA6/myc-His plasmid was 
transfected in another 25-cm2 flask served as control. Lipofectimine2000 transfection 
reagent was added into a 25-cm2 flask to sever as another control to compare the 
effects of transfection reagent on the NSC-34 cells. The cells were incubated at 37°C 
in a CO2 incubator for 48 hours before seeding into the 24-well plate for cytotoxicity 
assay. 
 
2.7.2.2. Treatment of transfected NSC-34 cells with LPS-BVCM 
The control and transfected cells were washed with DMEM/F12 twice before seeding 
into Poly-D-lysineand Collagen coated coverslips in the 24-well plate in DMEM/F12 
(Invitrogen, USA) at 1x105cells/well. After 24 hours incubation at 37°C in a CO2 
incubator, 25% and 75% of LPS-BVCM were added into the cells. The cells were 
treated by LPS-BVCM for 36 hours before the MTS assay was carried out to 
investigate the cell viability. 
 
2.8. Immunocytochemistry 
2.8.1. Double-labelling of Mitochondria with Diva  
Before doing the immunocytochemistry, MitoTracker Red CMXRos (M7512, 
Molecular probe, USA) were added into the culture medium at final concentration of 
300nM and incubate for 30 minutes. The MitoTracker Red CMXRos is a red-
fluorescent dye that stains mitochondria in living cells and its accumulation is 
dependent upon membrane potential. The dye is well-retained after fixation. After the 
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30 minute incubation, the NSC-34 cells on poly-D-lysine and collagen coated 
coverslips were washed gently with PBS for five minutes following a fixation in 4% 
PF for 15 minutes. The coverslips were rinsed for 10 minutes in 0.1% PBS-TX 
solution to wash away the residue PF and then were blocked by 5% normal rabbit 
serum for 1 hour. The coverslips were subsequently incubated with the primary 
antibodies against Diva (1:50, SC-8740, SantaCruz, USA) overnight at 4°C. After 
incubation with the primary antibodies, cells were washed 3 times with 1% PBS-TX 
for about 15 minutes and incubated for 1 hour in biotinylated rabbit anti-goat 
secondary antibody (1:250, Vector Laboratories, USA). Then the cells were washed 3 
times with 1% PBS-TX buffer for 15 minutes, and incubated with Avidin-FITC 
(Vector Laboratories, USA) for 30 minutes. Finally the coverslips were washed with 
0.1% PBS-TX for 3 times and mounted using fluorescent mounting medium 
containing DAPI (Vector Laboratories, UK). 
 
2.8.2. Detection of expression of Diva after transfection 
The overexpressed Diva with correct sequence should contain a myc-tag which 
enables us to distinguish it from endogenous expressed Diva by double-labeling 
immunocytochemistry using anti-myc and anti-Diva antibody. Double labeling of 
Diva and myc-tag were carried out using sequential immunocytochemistry method.  
 
2.8.2.1. Labeling of Diva by FITC 
After 72 hour incubation, the NSC-34 cells on poly-D-lysine and collagen coated 
coverslips were washed gently with PBS for 5 minutes following a fixation in 4% PF 
for 15 minutes. The coverslips were rinsed for 10 minutes in 0.1% PBS-TX solution 
 72
to wash away the residue PF and then were blocked by 5% normal donkey serum for 
1 hour. The coverslips were subsequently incubated with the primary antibodies 
against Diva (1:50, SantaCruz, USA) overnight at 4°C. After incubation with the 
primary antibodies, cells were washed 3 times with 1% PBS-TX for about 15 minutes 
and incubated for 1 hour in biotinylated donkey anti-goat secondary antibody (1:250, 
SantaCruz, USA). Then the cells were washed 3 times with 1% PBS-TX buffer for 15 
minutes, and incubated with Avidin-FITC (Vector Laboratories, USA) for 30 minutes.  
 
2.8.2.2. Labeling of myc-tag by rhodamine 
After the labeling of Diva by FITC was completed, the labeling of myc-tag were 
carried out by using the Mouse On Mouse (M.O.M.) labeling kit (Vector, USA) 
which is designed specifically for the localization of mouse primary monoclonal and 
polyclonal antibodies on mouse tissue and minimized the unspecific banding of anti-
mouse secondary antibody with the endogenous mouse immunoglobulins. The steps 
were done in the dark to prevent the bleaching of FITC fluorescence. Briefly, the cells 
were washed (2 x 5 minutes) in 0.1% PBS-TX and incubated for 1 hour in working 
solution of M.O.M. Mouse Ig Blocking Reagent (supplied in the kit). After 2 x 2 
minutes washing in 0.1% PBS-TX, the cells were incubated for 5 minutes in working 
solution of M.O.M. diluent (supplied in the kit). Then the cells were incubated with 
anti-myc antibody (1:200, Abcam, USA) which was diluted in M.O.M. diluent 
overnight at 4°C.  The next day, cells were washed for 3 x 10 minutes 0.1%  in PBX-
TX and incubated with M.O.M. Biotinylated Anti-Mouse IgG reagent (1:250, 
supplied in the kit) which was also diluted in the M.O.M. diluent for 1 hours at room 
temperature. After 3 x 10 minute washing in 0.1% PBS-TX, the cells were incubated 
with Avidin-Rhodamine (1:300, Vector, USA) for 30 minutes at room temperature. 
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Finally the coverslips were washed with 0.1% PBS-TX buffer (3 x 10 minutes) and 
mounted using fluorescent mounting medium containing DAPI (Vector, UK). All the 
fluorescence figures were taken using Olympus Fluoview FV1000 Laser Scanning 
Confocal Microscope.  
 
3. Results 
3.1. Expression of Bcl-2 family members in NSC-34 cells after being treated with 
different concentrations of LPS-BVCM 
The real-time PCR was used to investigate the expression of Bcl-2 family members 
after the NSC-34 cells were treated with 25% or 75% of 1μg/ml LPS stimulated 
































The specificity of real-time PCR products for each gene was also examined by 
running in 1.5% agarose gel and the results showed that the products were specific 
and the sizes were correct responding to each gene (Fig. 12).  
 
After the specificities of the primers were investigated, the expression of each Bcl-2 
family member was examined. The results in previous chapter have shown that 25% 
Figure 12. Electrophoresis of real-time PCR products of Bcl-2 family 
members  
 The size of real-time PCR products were indicated due to the 100bp markers in 1.5% 
agarose gel by electrophoresis. The bands are single and clear and the sizes are correct 
due to the design of each primers.  
Blk=229bp, Bok=186bp, Bad=187bp, Bid=206bp, Bax=173bp, BimL=244bp,  
Bcl-xL=157bp, Bcl-2=166bp, Bcl-w=158bp, Mcl-1=165bp, Diva=240bp, Gapdh=223bp 
Figure 11. Melting curves and peak area of primers of Bcl-2 family members 
in real-time PCR  
The melting curve analysis monitored by the LightCycler Instrument shows that the peak 
area for each primer is single and sharp which indicates that the products are specific 
and no primer-dimers are formed. 






1μg/ml LPS stimulated BVCM (LPS-BVCM) in DMEM/F12 could increase the 
viability of NSC-34 cells whereas 75% caused decreased viabilities and induced 
apoptosis. Figure 13 shows the expression change of Bcl-2 family members after the 
NSC-34 cells were treated with 25% or 75% LPS-BVCM in DMEM/F12 for 36 hours. 
After treated with 75% LPS-BVCM, the expression of Bcl-xL and Blk increased 
compared to the control, but the expression of Bad decreased. No significant 
expression changes were observed for other Bcl-2 family members. However, only 
Diva showed a significant increase in expression after the NSC-34 cells have been 
treated with 25% LPS-BVCM compared to both control and 75% treated sample.    
 78
Figure 13. Expression of Bcl-2 family members in NSC34 cells after being 
treated with 25% and 75% 1μg/ml LPS stimulated BVCM in DMEM/F12  
NSC34 cells were treated with 1μg/ml LPS stimulated BV-2 conditioned media in 
DMEM/F12 for 36 hours. The expressions of Bcl-2 family members were investigated 
using real-time RT-PCR. Among the anti-apoptotic members, only the expression of Bcl-
xL increases after treatment with 75% LPS-BVCM for 36 hours. Bad, one of the BH-3 
pro-apoptotic members shows significant decrease in its expression compared to that of 
the control after treated with 75% LPS-BVCM. However, the expression of another BH-3 
pro-apoptotic member, Blk, increases after treated with 75% LPS-BVCM. Another 
interesting finding is that the expression of Diva increases after NSC-34 cells are treated 
with 25% LPS-BVCM compared to both the control and the 75% treated sample.   
 
3.2. Immunostaining of Diva after treatment with 25% LPS-BVCM in NSC-34 
cells 
Real-time PCR results showed that the Diva expression increased after being treated 
with 25% of LPS-BVCM. By double immunostaining, the intensity of Diva staining 
increased. Colocalization of Diva with mitochondria was also seen after the NSC-34 







Figure 14. Double labeling of Diva and mitochondria after treatment with 
25% LPS-BVCM in NSC-34 cells  
NSC34 Cells were treated by 0% (A, B, C) and 25 % LPS-BVCM (D, E, F) respectively, 
for 24 hours. Mitochondria are visualized by MitoTracker (red) and Diva visualized by 
goat anti-Diva antibody (Green). From A and D, the expression of Diva are higher in 
25% LPS-BVCM treated sample (D) comparing with that in the untreated control (A). The 
merged pictures (C and F) show that the co-localization of Diva with mitochondria is 
(arrows) indicated by the yellow color is more intense in LPS-BVCM treated sample (F) 
than the untreated control (C) which suggests the translocation of Diva onto the 




3.3. Construction of Overexpression Plasmid for Diva 
The Diva function during apoptosis has been contradictory. In order to further 
investigate what the function of Diva is during the interaction between BV-2 
microglia and NSC-34 neurons, an overexpression plasmid for Diva was constructed 
using pcDNA6/myc-His© mammalian expression kit. First, the ORF was cloned from 
NSC-34 cells by PCR. The PCR product was examined by electrophoresis in 1.5% 
agarose gel. Figure 15 shows that the size of the PCR products was around 580bp 






Figure 15. Electrophoresis of Diva ORF  
Diva ORF was cloned from NSC-34 cells. Electrophoresis shows that the band for PCR 
product is around 580bp which is similar to Diva ORF.  
 
In order to guarantee the sequence of the ORF is 100% correct to the Diva ORF, the 
PCR product was cut out and the DNA was extracted and sent for sequencing. The 
sequence result showed that the PCR product was identical to the Diva ORF by 
comparing with the Diva CDS (Gene Bank Access No. AF067660). This result also 
indicates that the Diva is expressed in the NSC-34 cells.  
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The Diva ORF, which was extracted from the gel, was used as template. The restrict 
enzyme sites were added to the 5’ end and 3’end respectively. The two restrict 
enzymes were HindIII for 5’-end and XhoI for 3’-end. The PCR product was also 
examined by electrophoresis. Figure 16 shows that the size of the PCR products was 










Figure 16. Electrophoresis of Diva ORF-RE.  
Restrict enzyme sites were added to the Diva ORF by PCR. The product was examined in 
1.5% agarose gel by electrophoresis. Electrophoresis shows that the band for PCR 
product is around 594bp.  
 
The DNA of Diva ORF-RE was also extracted and double digested by HindIII and 
XhoI. At the same time, pcDNA6/myc-His was also digested by HindIII and XhoI in 
another tube. The digested DNA was run in 1.5% agarose gel and the corresponding 
DNA was extracted and purified (Fig. 17) by the QiaGen Gel Extraction Kit before 




















Figure 17. Electrophoresis of double digested Diva ORF-RE and pcDNA6  
After double digested by HindIII and XhoI, the digested DNA of Diva ORF-RE (B) and 
pcDNA6 (A) were run on 1.5% agarose gel and the corresponding sized bands were cut 
out for extraction and purification.  
 
After the double digested DNA were purified, the concentrations of the DNA were 
measured and the ligation reaction was carried out. After overnight reaction at 16°C, 
the ligased plasmids were transformed into the DH5α and the ampicillin-resistant 
clones were picked out and the plasmid was extracted and sent for sequencing. Figure 
18 shows that one of the plasmid has the correct Diva ORF inserted and this correctly 




Figure 18. Blasting result of pcDNA6-Diva  
Blast result showes that the 100% correct Diva ORF is inserted into the pcDNA6 plasmid.  
 
3.4. Overexpression of pcDNA6-Diva in NSC-34 cells 
3.4.1. Optimization of transfection condition of pcDNA6-Diva into NSC-34 cells  
The transfection conditions of pcDNA6-Diva into the NSC-34 cells were optimized 
by varying the ratio of plasmid to lipofectamine2000 reagent. The ratios tried were 
1:0.5, 1:1, 1:2.5 and 1:5. After 48 hour transfection, the total RNA was extracted and 
the expression of Diva was examined by real-time PCR. Figure 19 shows that after 48 
hour transfection, the ratio of plasmid to lipofectamine2000 at 1:1 could result in the 
highest increased expression of Diva, which was 4 times in comparison to that of the 
untransfected control.  
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 Figure 19. Expression of Diva in NSC-34 cells after being transfected with 
pcDNA6-Diva for 48 hours  
NSC-34 cells were transfected with different ratio of plasmid to lipofectamine2000 
transfection reagent. The picture shows that when transfected pcDNA6-Diva with 
lipofectamine2000 at 1:1, the expression of Diva increases the most, i.e., 4 times in 
comparison to that of the un-transfected control.  
 
3.4.2. Double labeling of myc-tag and Diva after transfection with pcDNA6-Diva 
After transfected with pcDNA6-Dvia, the overexpressed tagged Diva was visualized 
by double immunofluorensence labeling. The results showed that the Diva was 
perfectly colocalization with the myc-tag in some NSC-34 cells which indicated that 





Figure 20. Visulization of tagged Diva by immunocytochemistry 
NSC-34 neurons were transfected with pcDNA6-Diva for 48 hours and then triply stained 
with DAPI (blue for nucleus), goat anti-Diva antibody (green) and mouse anti-myc by 
rhodamine fluorescence (red). Note that diva is expressed in both the transfected and 
none-transfected NSC-34 cells (A), however, only the successfully transfected NSC-34 
cells show the red color (B).  The picture C shows the colocalization of Diva and myc-tag 
(arrows), indicating the specificity of the goat anti-Diva antibody.  (Bar=20μm) 
 
3.5. Proliferation assay of NSC-34 cells after being transfected with pcDNA6-
Diva 
After the optimized transfection condition was established, the effect of Diva on the 
proliferation in NSC-34 cells was examined. The NSC-34 cells were transfected with 
pcDNA6-Diva for 24 hours and the cells were seeded into 96-well plates. Two hours 
later after the seeding, the cell viabilities were measured as the 24 hour viabilities and 
standardized to 100%. The viabilities of NSC-34 cells at 48, 72 and 96 hours were 
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investigated by MTS assay and calculated as the percentage of the 24 hour viabilities. 
The empty pcDNA6 plasmid transfected, un-transfected, and lipofectamine2000 
reagent treated cells served as the controls. Figure 21 shows that 48 hours after 
transfection, the pcDNA6-Diva transfected sample showed a significant increase in 
cell viability (155.05%) comparing to the untreated control (142.41%), 
lipofectamine2000 treated control (143.83%) as well as the empty pcDNA6 
transfected control (136.04%). However, 72 and 96 hours after transfection, no 
significant difference can be seen.   
 
Figure 21. Proliferation assay of NSC-34 cells after transfected with pcDNA6-
Diva  
48 hours after transfection with pcDNA6-Diva, the viability of pcDNA6-Diva transfected 
NSC-34 cells is higher than all the other three controls. However, 72 and 96 hours after 






3.6. Effects of overexpression Diva in NSC-34 cells after treated with LPS-
BVCM 
After the NSC-34 cells were transfected with pcDNA6-Diva for 24 hours, the cells 
were seeded into the 24-well plate coated with poly-D-lysine and collagen in 
DMEM/F12. After 24 hour seeding, the cells were treated with 75% or 100% of 
1μg/ml stimulated BV-2 conditioned medium. After 36 hour treatment, the viabilities 
of NSC-34 cells were investigated by MTS assay. The cells in the DMEM/F12 were 
served as the control and the viability of each control were standardized to 100%. The 
viabilities of 75% and 100% LPS-BVCM treated samples were calculated as the 
percentage of the corresponding control for each treatment. MTS assay showed that 
the viability of pcDNA6-Diva transfected sample (91.2%) was higher than that of the 
untreated control (64.5%), lipofectamine2000 treated control (57.3%) or empty 
pcDNA6 transfected control (70.2%) after being treated with 75% LPS-BVCM for 36 
hours. When treated with 100% LPS-BVCM, the significant difference can only be 
seen between the pcDNA6-Diva transfected sample and the untreated control (Fig. 
22).  
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Figure 22. Viabilities of NSC-34 cells after transfected with pcDNA6-Diva and 
treated with LPS-BVCM for 36 hours 
After treated with 75% LPS-BVCM, the viability of pcDNA6-Diva transfected (91.2%) is 
higher than the untreated control (64.5%), lipofectamine2000 treated only control 
(57.3%) and pcDNA6 transfected control (70.2%). But when treated with 100% LPS-
BVCM, no difference is seen between the pcDNA6-Diva transfected sample and 
lipofectamine2000 treated control or pcDNA6 transfected control. The significant 
difference is only observed between the pcDNA6-Diva transfected sample (59.7%) and the 
untreated control (50.1%) (**: p<0.01; *: p<0.05).   
 
4. Discussion 
In previous chapter, it has been noted that the 1μg/ml LPS stimulated BV-2 
conditioned media (LPS-BVCM) have both protective and toxic role on the NSC-34 
cells depending on the concentrations of LPS-BVCM in the DMEM/F12. High 
concentrations of LPS-BVCM can induce apoptosis of NSC-34 cells.  
 
4.1. Microglial toxicity could result in changes in expressions of several Bcl-2 
family members in NSC-34 cells 
In this chapter, the expressions of Bcl-2 family members, which play important role in 
regulating the apoptosis processes, were investigated by real-time PCR. The PCR 
results showed that when treated with 25% LPS-BVCM which corresponds to the 
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protective role of microglia, only the Diva expression increased. But when treated 
with 75% of LPS-BVCM, several members of Bcl-2 family members showed the 
expression changes, including the increased expressions of Bcl-xL and Blk as well as 
a decreased expression of Bad. Bcl-xL can operate as the upstream regulator and 
oppose the intrinsic death-inducing actions of other Bcl-2 family members such as 
Bax and Bak at mitochondrial membranes (Wei et al., 2001). Bad was reported to be 
able to selectively bind to Bcl-xL and reversed its death repressor activity (Yang et al., 
1995). Then increased expression of Bcl-xL and decreased expression of Bad may 
present a possible regulating mechanism which may be intended to protect the NSC-
34 cells when facing the BV-2 conditioned cytotoxicity. However, Blk was reported 
to interact with both the Bcl-2 and Bcl-xL and was defined as a potent death agonist 
(Hegde et al., 1998). The increased expression of Blk when treated with 75% LPS-
BVCM may counteract the protective role of Bcl-xL and facilitate the microglia 
induced apoptosis in NSC-34 cells.  
 
4.2. Micoglial neuroprotective effects could lead to an increase only in Diva 
expression in NSC-34 cells among the Bcl-2 family members 
When the NSC-34 cells were treated by 25% LPS-BVCM, the LPS-BVCM showed 
protective effects by increasing viability of NSC-34 cells and promoting growth of the 
processes of NSC-34 cells. One of the interesting finding in the present study is that 
only the Diva expression was increased after the NSC-34 cells were treated with 25% 
LPS-BVCM. The function of Diva during the apoptosis has been contradictory. Diva 
was reported to be able to interact directly with Apaf-1 and inhibited the binding of 
Bcl-xL to Apaf-1. The inhibiting of binding of Bcl-xL to Apaf-1 can counteract the 
anti-apoptotic role of Bcl-xL and promote apoptosis by Apaf-1 activated caspases-9 
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(Inohara et al., 1998). On the other hand, Diva was also reported to possess anti-
apoptotic role by interfering with apoptotic signaling downstream of cytochrome c 
release. More interestingly, the Diva was reported to be able to promote the exit of 
cell cycle in glioma cells (Naumann et al., 2001).  The roles of Diva in anti-apoptosis, 
pro-apoptotosis and possible involvement in the cell cycle regulation have been 
indicated by previous studies. In addition, the present study further showed that the 
increased expression of Diva in NSC-34 cells when treated with 25% LPS-BVCM. 
All these imply that Diva might occupy a possible nodal position in the fate 
determination of a cell.  
 
4.3. Micrglial neuroprotective effects could lead to the translocation of Diva from 
cytosol to mitochondria in NSC-34 cells 
Another interesting finding is that after being treated with 25% LPS-BVCM, a 
translocation of Diva onto the mitochondria was investigated. By the double 
immunostaining, the MitoTracker showed the mitochondria and the FITC showed the 
location of Diva. From the results, the colocalization of Diva and mitochondria was 
obvious. Diva has been reported to have a transmembrane domain at it C-terminal 
(Inohara et al., 1998;Song et al., 1999) which is similar to some other Bcl-2 family 
members such as Bcl-2, Bcl-xL. Bcl-2 and Bcl-xL have been reported to be able to 
translocate onto the mitochondria by the TM domain. Either by preventing the release 
of cytochrome-c or regulating the electrical and osmotic homeostasis of mitochondria, 
Bcl-2 and Bcl-xL exerted their anti-apoptotic function and inhibited the activation of 
the downstream executor caspases-9 (Kluck et al., 1997;Vander Heiden et al., 
1997;Yang et al., 1997). However, when the NSC-34 cells were treated with 25% 
LPS-BVCM, the conditioned medium presented a protective role on the NSC-34 cells 
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by promoting both the proliferation and the growth of the processes and it was not 
related to the anti-apoptotic role. The detailed mechanisms of protection after the 
translocation of Diva onto the mitochondria when the NSC-34 neurons were treated 
with 25% LPS-BVCM still need to be further identified.  
 
4.4. Overexpression of Diva could present neuroprotective effects 
4.4.1. The overexpression plasmid for Diva were functional and the Diva could 
be correctly expressed in the NSC-34 cells 
In order to investigate the real function of Diva in the NSC-34 cells, an 
overexpression plasmid was constructed and transfected into the NSC-34 cells. The 
sequence inserted into the overexpression plasmid has been confirmed by sequencing 
and was found to be identical to the Diva CDS (Gene Bank Access No. AF067660). 
Although Diva was found to be expressed in the NSC-34 cells, the overexpressed 
Diva contains a myc-tag and could be recognized by anti-myc antibody. By double 
immunostaining, the constructed protein was identified in the NSC-34 cells by anti-
Diva and anti-myc-antibodies after transfection. The green color in figure 20 shows 
the localization of Diva and indicates that the Diva was routinely expressed in the 
normal NSC-34 cell which was coincident with the PCR results.  The red color in 
figure 20 shows the localization of myc-tag which also indicated the location of 
constructed Diva protein. The merged picture in Figure 20 shows the colocalization of 
Diva and myc-tag by the yellow color. The results not only show that the plasmid is 
able to overexpress the correct Diva protein in the NSC-34 cells after transfection, but 
also indicate that the specificity of the anti-Diva antibody to the Diva protein during 
the immunocytochemistry process.  
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After confirming the validity of the overexpression plasmid, the further optimized 
transfection efficiency was carried out by using the lipofectamine2000 transfection 
reagent. The effects of transfected plasmid depended on the ratio of DNA and 
transfection reagent as well as different type of cells. Four ratios of DNA: 
lipofectiame2000 were tried on the NSC-34 cells in the present study. Forty-eight 
hours after transfection, the expression of Diva was investigated by real-time PCR. 
When NSC-34 cells were transfected at the ratio of 1:1, the expression of Diva in the 
cells was highest, i.e., 4 times higher in comparison to that of the control.  
 
After confirmation of the validity of the plasmid and optimization of the transfection 
condition, the transient transfection was carried out. During each experiment, the 
untreated NSC-34 cells, the lipofectamine2000 only treated NSC-34 cells and the 
empty pcDNA6 plasmid transfected NSC-34 cells all served as controls to compare 
the possible effects of transfection reagent or pcDNA6 plasmid on the NSC-34 cells. 
All the experiments were carried out at the same time to minimize the variance.  
 
4.4.2. Overexpression of Diva in NSC-34 cells increased the proliferation rate 
First, it has been examined if the overexpression of Diva could have any effect on 
proliferation of NSC-34 cells. By the MTS assay, 48 hours after the transfection, the 
pc-DNA6-Diva transfected NSC-34 cells showed a significant increase in the viability 
(Fig. 21). This indicates that Diva could promote proliferation rate of NSC-34 cells. 
However, at 72 or 96 hours, the difference was not significant (p>0.05). This may be 
due to the transient overexpression of Diva. However, the current results are different 
from Nuamann’s previous study. Naumann and co-workers reported that Diva could 
promote the exit of cell cycle in the glioma cells and arrested the cell in the G0/G1 
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phase which resulted in a stop of proliferation (Naumann et al., 2001). On the other 
hand, Diva is structurally similar to the anti-apoptotic members of Bcl-2 family 
including Bcl-2, Bcl-xL and Bcl-w.  It contains all the four BH domains (BH1-BH4) 
as well as a c-terminal transmembrane domain (TM). The structure of Diva and some 
other Bcl-2 family members are shown in figure 23.  Previous studies have also 
indicated that Bcl-2 could not only inhibit apoptosis, but also restrain cell cycle entry 
(Huang et al., 1997). Although all the evidence shows the great possibility that Diva 
may suppress the cell cycle, to overexpress Diva in the NSC-34 cells in the present 
study eventually increased the viability of NSC-34 cells. One possible reason to 
explain this contradictory is that, in Nuamann’s study, the Diva of the mouse was 
transfected into a human cell line. However, the homologue of Diva in Human is Bcl-
B. The slight difference between the peptide sequence of Diva and Bcl-B may be 




4.4.3. Overexpresson of Diva protected NSC-34 cells from microglial cytotoxicity 
The effect of overexpression of Diva on the microglia cytotoxicity was also examined. 
After Diva was overexpressed in the NSC-34 cells, 75% and 100% LPS-BVCM were 
added into the NSC-34 cells for 48 hours after transfection. After 36 hour treatment, 
the viability of overexpressed NSC-34 cells under the 75% of LPSBVCM treatment 
Figure 23. Structure of Bcl-2 family members.  
The anti-apoptotic members in the Bcl-2 family including Bcl-2, Bcl-xL, Bcl-w and 
contain all the 4 BH domains. Another anti-apoptotic member is Mcl-1 which does not 
contain BH4. Some Bcl-2 family members only contain BH3 domain and are called BH-3 
only members including Bad, Blk, Bid and BimL which are pro-apoptotic members. Bax 
and Bok are the other two pro-apoptotic members and also do not contain BH4. However, 
Diva contains all the BH1-BH4 domains and has a TM domain at the C-terminal which is 













BH3 BH1 BH2 
was significantly higher than the untreated control, lipofectamine2000 treated control 
and the empty pcDNA6 transfected control (Fig. 22).  These results indicate that Diva 
could play a protective role on the NSC-34 cells during the microglia cytotoxicity. 
Although the current results are contradictory to Inohara’s study in which Diva was 
indicated to possess a pro-apoptotic function and can induce BH3-independent cell 
death (Inohara et al., 1998),  the current observation is coincident with Song and 
Naumann’s studies. Song reported that Diva is a negative regulator of cell death and 
could interact with Apaf-1 and homodimerized or heterodimerized with some death-
promoting Bcl-2 family members to inhibit apoptosis (Song et al., 1999). Naumann 
reported that Diva could inhibit CD95 ligand or chemotherapeutic drugs induced 
apoptosis (Naumann et al., 2001). Moreover, the homologue of Diva in human, Bcl-B, 
has also been reported to be able to bind and regulate Bax and Bak induced apoptosis 




























Since the Diva protein may play an important role in mediating microglial dual 
functions in vitro, it would be interesting to explore if the similar mechanism could 
exist in an in vivo scenario. The distribution of the Diva in vivo has been therefore 
studied first in the current experiment. 
 
1. Introduction 
Previous studies showed not only the contradiction in functions of Diva in apoptosis 
but also in the distribution of Diva in vivo. Two papers have described the Diva 
distribution in vivo. In Inohara’s paper, Diva was reported to be expressed in 
embryonic tissues and strictly in adult Ovary and testis by Northern blot. At stage E15 
of the embryonic mouse, Diva was detected in brain, liver and heart. However, in the 
adult, Diva was only detected in granulose cells of the ovary and the seminiferous 
tubules of the testis (Inohara et al., 1998). On the other hand, in Song’s study, Diva 
was reported to be expressed in the E7 to E17 embryonic tissue. In the adult, only the 
ovary showed a strong positive hybridization and a weak hybridization for epididymis 
to Diva but not other tissues (Song et al., 1999).  
 
Both papers confirmed that Diva was expressed in the adult ovary and testis, but the 
expression of Diva in the mouse embryo is contradictory. In Inohara’s study, the 
expression of Diva in vivo was examined by Northern blot, in situ hybridization and 
RT-PCR analyses, which were all focused on the mRNA level. The brain was 
considered as a whole organ whereas it actually includes the cerebrum, cerebellum, 
and brain stem. In Song’s study, the expression of Diva in vivo was investigated by 
Northern blot which was also focused on the mRNA level (Inohara et al., 1998;Song 
et al., 1999).  
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The lack of proper antibody at that time may be the reason that no investigation at the 
protein level had ever been conducted. The low expression level of mRNA and the 
sensitivity of the Northern blot or in situ hybridization may also contribute to the 
contradiction between these two studies.  
 
In this chapter, the anti-Diva antibody, the specificity of which decribed in the 
previous chapter, was used to investigate the Diva distribution in mouse tissues. 
Mouse ovary will be used as the positive control. Immunohistochemistry, RT-PCR 
and whole mount in situ hybridization were employed.  
 
2. Materials and methods 
2.1. Animals 
Both 4-week male and female Swiss mice were used in the present study.  The mice 
were purchased from the Laboratory Animal Centre, Singapore. The mice were 
housed in clean cages in a temperature-controlled room with 14 hours light and 10 
hours dark schedule.  
 
2.1.1. Anaesthesia 
Prior to perfusion or harvesting of tissue samples and embryos, all animals were 
deeply anaesthetized by an intraperitonal injection of 7% chloral hydrate (5 ml/kg 
body weight) administered in the lower abdomen. After 10-15 minutes, one of the 
foot pads of the animals was pinched with a pair of toothed forceps to ensure the 
animals were under full anaesthesia. All procedures involving animals were approved 
by the Institutional Animal Care & Use Committee (IACUC), DSO National 
Laborotries, Singapore.  
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2.2. Immunohistochemistry 
2.2.1. Preparation of fixatives  
Materials           
4% paraformaldehyde (PF): 
   Paraformaldehyde (Sigma, USA)         40 g 
   0.1M phosphate buffer (pH 7.4)    1000 ml 
 
The pH was adjusted to 7.4 by adding 1N HCl solution. All fixatives used in the 
present study were freshly prepared before use. The paraformaldehyde solution was 
prepared by heating paraformaldehyde powder in 0.1M phosphate buffer (pH 7.4). It 
was subsequently cooled to the room temperature.  
 
2.2.2. Preparation of gelatinized slides 
Materials      
5% gelatin solution:  
   Gelatin                    1.5mg 
   Chrome Alum         0.15g 
   Distilled water                   100ml 
Slides were first dipped in the acid solution (400ml of 98% sulfuric acid mixed with 1 
tea spoon of potassium dichromate) for 2 minutes, and then washed by running tap 
water for 10 minutes. The slides were rinsed with distilled water and then baked at 
80ºC in an oven overnight for drying. The following day, dried slides were dipped in 
the gelatin solution and were then hung to dry with the clips. Gelatinized slides were 
kept in a 37ºC oven for immunohistochemical studies.   
 
 100
2.2.3. Perfusion procedure 
A midline incision of the skin from the level of the suprasternal notch to the level 
above the symphysis pubis was made. The incision, made through the skin and 
muscles of the anterior abdominal wall, was extended bilaterally along the subcostal 
margins to expose the sternum and diaphragm. The latter was then cut along the 
subcostal margin to fully expose the heart. Care was taken during this process in order 
not to damage the lungs. The pericardium was then slit with a pair of fine scissors to 
fully expose the heart. The perfusion was carried out under gravity with the reservoirs 
containing the fixative and Ringer’s solution fixed at a height of about 100 cm above 
the animal. Perfusion was initiated whereby a cannula with some Ringer’s solution 
dripping slowly from its tip was inserted into the left ventricle and was immediately 
followed by slitting a portion of the right atrium to let out the blood, and subsequently 
the perfusate. Once the cannula was secured in place, the flow of the Ringer’s solution 
was turned to full pressure by means of a three-way tap. A total of 150-200 ml of 
Ringer’s solution at room temperature was allowed to flush the vascular system until 
the lungs and liver were cleared of blood. A total of about 200 ml of the fixative (4% 
PF) at room temperature was then administered. 
 
2.2.4. Tissue sampling 
Four-week old mice were used for the DAB staining. The tissues for the 
immunohistochemistry included the cerebrum, brain stem and spinal cord. The mouse 





2.2.5. Preparation of frozen sections 
The tissues were subsequently transferred to 0.1M phosphate buffer (pH7.4) 
containing 20-30% sucrose and kept overnight at 4°C. The tissue samples were 
mounted on a metal chuck using Lipshaw M-1 embedding matrix (Pittsburgh, USA) 
and rapidly frozen by quenching in liquid nitrogen. Coronal sections of 20μm 
thickness of tissues were cut using a cryostat (Leica CM 3050). The sections were 
subsequently mounted on gelatinized slides and allowed to dry at room temperature 
for 1 hour. 
 
2.2.6. DAB Immunohistochemistry  
Materials 
1x PBS: 
   Di-sodium hydrogen phosphate heptahydrate              13.3g 
   Sodium chloride                                                         8.5g 
   Distilled water to make up to                                     1000ml 
The solution was adjusted to pH 7.4 with 1N hydrochloric acid (HCl). 
 
PBS-TX: 
   Triton-X 100                      1ml 
   PBS                                        1000ml 
 
0.05M Tris buffered saline (TBS; pH 7.6): 
   Tris base (Trihydroxymethylaminomethane)                  6g 
   Sodium chloride                                                    8g 
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   Distilled water                1000ml 
pH was adjusted  with 1N HCl        
             
0.1% ammonium nickel sulphate Tris buffered saline (TBS; pH 7.6): 
   Ammonium nickel sulphate                            1g 
   TBS                                           1000ml 
 
3,3’  diaminobenzidine tetrahydrochloride (DAB) solution: 
   DAB                                         50mg 
   30% hydrogen peroxide                               33µl  
   TBS                                      100ml 
 
Frozen sections mounted on gelatinized slides were air dried for 2 hours. The slides 
were rinsed for 30min in 0.1% PBS-TX solution. Sections were then blocked with 5% 
normal rabbit serum for 1 hour, and subsequently incubated with the anti-Diva 
antibody (1:100, Santa Cruz, USA) overnight at room temperature. After incubation 
with the primary antibody, tissue sections were washed 3 times with 1% PBS-TX for 
about 15 minutes. They were incubated for 1 hour in biotinylated rabbit anti-goat 
secondary antibodies (1:250, Vector Lab., USA). The sections were washed with 
PBS-TX buffer, and incubated with Avidin-Biotin complex (ABC reagent, Vector 
Lab., USA) for 1 hour. Immunostaining was visualized with diaminobenzidine (DAB, 
Sigma, USA) as a peroxidase substrate. The reaction product was intensified with 
0.1% ammonium nickel sulphate. The tissue sections were finally counter-stained 
with 1% methyl green, dehydrated in graded concentrations of alcohol and mounted 
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in Permount. The sections processed following similar steps but omitted primary or 
secondary antibody served as the control. 
2.2.7. Fluorescent double-labelling of Diva with nervous system cell markers  
Double-labelling of Diva with some specific cell markers was performed to identify 
the cell type with expression of Diva in the CNS. The antibodies and concentrations 
used in the present study are list in Table 5. 
Table 5. Antibodies used for fluorescent double-labelling immunohistochemistry 
Markers Cell Type Concentraion 
Rabbit anti-NG2 (Chemicon, USA) NG-2 cells (possible 
oligodendrocyte precursor) 
1:200 
Rat anti-CD11b (Pharmingen, USA) Microglia 1:200 
Rabbit anti-NFH (Chemicon, USA) Neurons 1:200 
Mouse anti-CNPase (Chemicon, USA) Oligodendrocytes 1:200 
Rabbit anti-GFAP (Dako, Denmark) astrocytes 1:200 
 
The sections of the spinal cord were used to carry out the double labelling of Diva 
with different cell types. The frozen sections mounted on gelatinized slides were 
rinsed in PBS-TX for 10 minutes. Sections were then blocked by 5% normal rabbit 
serum for 1 hour, and subsequently incubated with the anti-Diva antibody (1:100, 
Santa Cruz, USA) overnight at room temperature. After incubation with the primary 
antibody, tissue sections were washed 3 times with 1% PBS-TX for about 15 minutes. 
They were incubated for 1 hour in biotinylated rabbit anti-goat secondary antibodies 
(1:250, Vector Lab., USA). The sections were washed with PBS-TX buffer, and 
incubated with Avidin-FITC (1:300, Vector Lab., USA) for 30 minutes. After 
washing with PBS-TX for 3x10 minutes, the sections were blocked with 5% of the 
serum for 1 hour and then incubated with antibody of specific cell marker at room 
temperature overnight. The next day, the sections were first washed with PBS-TX 3 x 
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15 minutes and incubated with cy3 or rhodamine conjugated secondary antibody for 1 
hour. After being washed with PBS-TX for 3 x 5 minutes, the coverslips were 
mounted using fluorescent mounting medium containing DAPI (Vector, UK). All the 
fluorescence pictures were taken using Olympus Fluoview FV1000 Laser Scanning 
Confocal Microscope.  
 
3. Results 
3.1. DAB immunohistochemistry of Diva in the central nervous system 
Several different tissues from either male or female adult mice at age of 8 weeks were 
used for DAB immunohistochemistry. Figure 24 shows that no positive staining can 
be seen in the cerebrum. However, in the mid-brian, pons and spinal cord, some 
specific staining in cells of some nuclei could be observed. Figure 25 shows that the 
cells in the RLi-rostral linear nucleus of the raphe of the mid-brain were specifically 
positive. Figure 26 shows that cells in facial nucleus (7N) in the  pons also have been 
specifically stained. In the hypoglossal nucleus (12N), positive staining can also be 







Figure 24. Immunostaining of Diva in the cerebrum  





Figure 25. Immunostaining of Diva in the mid-brain  
Positive staining of Diva can be observed in the rostral linear nucleus of the raphe (RLi).  





Figure 26. Immunostaining of Diva in the pons  
Positive staining of Diva can be observed in the facial  nucleus (7N).  (A: 10x, B: 20x, C: 







   
Figure 27. Immunostaining of Diva in the medulla oblongata  
Positive staining of Diva can be observed in the hypoglossal nucleus (12N).  (A: 10x, B: 







Figure 28. Immunostaining of Diva in the spinal cord  
Positive staining of Diva (arrows) can be observed in the ventral horn of spinal cord.  (A: 
10x, B: 40x Bar=50μm, C: 40x, D: 100x, E: 100x) 
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3.2. Double labeling of Diva with cell specific markers in the CNS 
Double labeling of Diva with various cell specific markers showed that there were no 
double-labeling of Diva with NG-2 (Fig 29), GFAP (Fig 30), CD11b (Fig. 31) and 
CNPase (Fig. 32). However, the colocalization of Diva with NFH could be seen (Fig. 
38) which indicates that Diva is specifically expressed in neurons but not microglia, 
astrocytes, oligodendrocytes and their precursors. 
B A 
C D 
Figure 29. Double labeling of Diva and NG2 in the ventral horn of the spinal 
cord 
NG-2 positive cells are visualized by anti-NG2 antibody (Red) and Diva is visualized by 
goat anti-Diva antibody (Green). DAPI is used to label the nucleus (Blue). No 






Figure 30. Double labeling of Diva and GFAP in the ventral horn of the spinal 
cord 
Astrocytes are visualized by anti-GFAP antibody (Red) and Diva by goat anti-Diva 
antibody (Green). DAPI is used to label the nucleus (Blue). No colocalization of Diva and 








Figure 31. Double labeling of Diva and CD11b in the ventral horn of the 
spinal cord 
Mciroglia are visualized by anti-CD11b antibody (Red) and Diva visualized by goat anti-
Diva antibody (Green). DAPI is used to label the nucleus (Blue). No colocalization of 










Figure 32. Double labeling of Diva and CNPase in the ventral horn of the 
spinal cord 
Oligodendrocytes are visualized by anti-CNPase antibody (Red) and Diva by goat anti-
Diva antibody (Green). DAPI is used to label the nucleus (Blue). No colocalization of 






Figure 33. Double labeling of Diva and NFH in ventral horn of the spinal cord 
Neurons are visualized by anti-NFH antibody (Red) and Diva by goat anti-Diva antibody 
(Green). DAPI is used to label the nucleus (Blue). Colocalization of Diva and NFH 




The distribution of Diva in vivo has been contradictory based on previous studies. The 
expression of Diva was mainly investigated by Northern blot.  In the present study, 
the immunohistochemistry was employed to investigate the expression of Diva in vivo. 
The specificity of the goat anti-Diva antibody (Santa Cruz, USA) has been tested in 
previous experimental study.  By double-labeling of overexpressed Diva protein with 
the myc-Tag, the antibody was shown to specifically recognize the Diva protein with 
a colocalization immunoreactivity with the myc-tag.  
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4.1. DAB immunostaining showed that positive staining of Diva can be seen in 
the brain stem and spinal cord 
In order to investigate the special distribution of Diva in the CNS, DAB 
immunohistochemistry was employed. Positive staining of Diva has been seen in 
some specific nuclei in the brain stem. The positive staining of Diva in the brain stem 
mainly located in the hypoglossal nucleus (12N) of medulla oblongata, facial nucleus 
(7N) of pons and rostral linear nucleus of the raphe (RLt) of midbrain. In the spinal 
cord, the positive staining cells could also be observed mainly in the ventral horn. In 
previous studies, the brain was reported to be negative for Diva, in concert with the 
current observation that Diva was not expressed in the cerebrum. 
 
4.2. Double fluorencent immunostaining indicated that Diva is expressed in 
neurons in the CNS but not oligodendrocyte, astrocyte, NG-2 cells or microglia 
In the spinal cord, the Diva was found to be expressed in the vental horn. The double 
labeling of Diva with several cell markers in the CNS was further carried out in order 
to investigate in which type of cells Diva is expressed. By double 
immunofluorenscence labeling, no colocalization of Diva with microglia, astrocytes, 
oligodendrocytes or NG-2 cells could be seen. However, the colocalization of Diva 
with NFH, a neuronal marker, has been observedd which indicates that Diva is 
expressed in certain neurons in the CNS.  
 
4.3. Diva in vivo function is still unknown  
Although Diva has been observed to be expressed in the neuronal NSC-34 cell line 
and related to protective function in response to microglial cytotoxicity, the 
distribution of the Diva protein is not universal in vivo. It may be true that the anti-
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apoptotic function may not be a crucial role for Diva. But, why would some tissues 
express this protein while other tissues do not? In the cell line, the cells possess the 
ability for indefinite self-renewal and yet they express the Diva protein.  In 
consideration of the possible roles of Bcl-2 family members in cell cycle, it is 
reasonable to assume that the Diva’s expression may be turned off after the cells 
differentiate into more mature status. 
 
If this assumption was true, the Diva expression may be found in stem cells. The 
protective role of Diva may be important for stem cells when they are transplanted 
into the CNS where the transplanted cells will face the challenges from 









































 This part of the study is focused to demonstrate expression of Diva in the stem cells 
during stem cell differentiation. The results may provide important information for 
future study  in vivo on the interaction between transplanted stem cells and other cells 
such as microglia in the CNS.   
 
1. Introduction 
In 1992, Reynolds, Weiss and colleagues demonstrated that cells isolated from the 
CNS of adult and embryonic mice and propagated in the presence of epidermal 
growth factor could give rise to large spheres of cells which was called termed 
“neurospheres.” These neurospheres possessed neurons, glia and cells expressing 
nestin, the intermediate filament previously associated with neuroepithelial cells. 
They showed that an entire neurosphere could be generated from a single cell and that 
this neurosphere could be subsequently dissociated to produce a new neurosphere that 
also contained neurons and glia. Thus, these neurosphere-producing cells have had the 
properties of a stem cell: they were self-renewing and multipotent (Reynolds et al., 
1992;Reynolds and Weiss, 1992). 
 
Later, this neural stem cell was found to be able to give rise to neurons, astrocytes and 
oligodendrocytes. Neural stem cells initially cultured as floating neurospheres in the 
presence of epidermal growth factor (EGF) were capable of differentiating into 
neurons, astrocytes and oligodendrocytes in vitro and following transplantation as 
well (Gage, 2000). This property makes neural stem cells a promising cell type for 
cell therapy in treatment of injuries or diseases in the CNS.  
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An important issue on neural stem cells is the neural stem cell cycle. Previous studies 
indicates that the key regulators of neural stem cell proliferation allow a greater 
degree of control to determine not only the number of cells within the CNS, but also 
the cell fate (Ohnuma et al., 2001;Ohnuma and Harris, 2003). In one series of 
experiments, it was demonstrated that lengthening of the cell cycle caused cortical 
progenitors to undergo differentiative divisions, whereas shortening the cell cycle 
results in more self-renewing divisions (Lukaszewicz et al., 2002). 
 
Bcl-2 family members have been indicated in the regulation of cell cycle by previous 
studies. It has been reported that the stimulation of cell proliferation could inhibit the 
cell differentiation and sometime induce cells to undergo apoptosis (Askew et al., 
1991;Askew et al., 1993). The earliest connection between Bcl-2 and cell-cycle was 
that the cell with overexpression of Bcl-2 protein was in the quiescent state after  it 
survived from growth factor-starvation-induced cell death (Vaux et al., 1988). Later, 
the anti-proliferative effect of Bcl-2 has been reported being shared by other Bcl-2 
family members including Bcl-xL (O'Reilly et al., 1996), Bcl-w (Huang et al., 1997) 
and myeloid cell leukemia sequence 1 （Mcl-1） (Fujise et al., 2000). While the anti-
apoptotic members of Bcl-2 family members can arrest the cell in the G0/G1 phase, 
the overexpression of pro-apoptotic Bax protein could result in an increased number 
of cycling thymocytes (Brady et al., 1996). Moreover, it has been demonstrated that 
the anti-proliferative effects of Bcl-2 protein could be counteracted by Bax (Borner, 
1996). All these observations demonstrate that overexpression of pro- and anti-




Based on previous researches, it is reasonable to hypothesize that the function of Bcl-
2 family members in the cell cycle may also affect the cell fate during the neural stem 
cell differentiation.  Diva is structurally similar to the Bcl-2 protein in which they all 
contain four BH domains as well as one TM domain at the c-terminal. Our current 
study have indicated that overexpression of Diva in the NSC-34 cells was able to 
promote the proliferation of the cells which is opposed to the previous findings of 
Diva’s pro-apoptotic function . In the present study, the gene expression of Diva was 
further investigated in cultured bone marrow stem cells and neural stem cells as well 
as during stem cell differentiation.  
 
2. Materials and methods 
2.1 Animals 
Twenty adult males (for isolation of bone marrow stem cells) and 10 pregnant females 
(embryos for isolation of neural stem cells) Swiss mice were used in the present study.  
The mice were purchased from the Laboratory Animal Centre, Singapore. The mice 
were housed in clean cages in a temperature-controlled room with 14 hours light and 
10 hours dark schedule.  
 
2.1.1 Anaesthesia 
Prior harvesting of tissues or embryos, all animals were deeply anaesthetized by an 
intraperitonal injection of 7% chloral hydrate (5 ml/kg body weight) administered in 
the lower abdomen. After 10-15 minutes, one of the foot pads of the animals was 
pinched with a pair of toothed forceps to ensure the animals under full anaesthesia. 
All procedures involving animals were approved by institutional animal care&use 
committee (IACUC), DSO National Laborotries, Singapore. 
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2.1.2 Confirmation of embryonic day  
Two to three female Swiss mice with one normal male mouse were placed in a cage 
overnight. Noon on the day when a copulation plug was observed was considered day 
0.5 of pregnancy. In total, about 60 embryos were collected on embryonic day 14.5 
(E14.5) for isolation of neural stem cells.  
 
2.2 Primary tissue culture 
2.2.1 Primary culture of embryonic neural stem cells (NSC) 
Materials: 
NSCs Complete Culture Medium (NSCCCM): 
     DMEM/F12 (130565, Invitrogen)                                                   46.5ml 
     EGF (2mg/ml, Invitrogen)                                                             0.005ml 
     B-27 supplement (50x, Invitrogen)                                                      1ml 
     200mM L-Glutamin (100x, Invitrogen)                                            0.5ml 
     Insulin-Transferrin-Selenium (ITS) (100x, Invitrogen)                    0.5ml 
     Antibiotic antimycotic solution (100x, Sigma)                                 0.5ml 
 
0.5% trypsin-EDTA solution (Sigma)                                 
 
Sterile PBS (pH7.4) (NUMI, Singapore)             
 
Fetal bovine serum (Hyclone) 
 
The primary culture of neural stem cells was derived from the E14.5 embryos of 
Swiss mice. The dissection instruments were soaked in a tray full of ethanol. The 
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pregnant mouse was lied on its back and swab with 70% ethanol. With sterile forceps 
and scissors, the uterus was dissected out and placed into a petri dish with steriled 
PBS. The embryos were isolated from the uterus and transferred to a second petri dish 
with steriled PBS.  
 
The forebrains of the embryos were dissected out and cut into small pieces in 
DMEM/F12 by using a fine pair of scissors. The fragmented tissues were put into a 
15ml tube with a sufficient volume of 0.25% Trypsin/EDTA in DMEM/F12 and 
incubated for 1 hour at 37°C with a shaking every 15 minutes. The digestion reaction 
was stopped by adding equal volume of DMEM/F12 supplied with 10% FBS. Cells 
were passed through Falcon 70μm cell strainer (352350, BD Bioscience, USA) to 
remove remaining clumps of tissue and centrifuged at 1200rpm for 5 minutes. The 
supernatant was removed and the pellet was resuspended in the NSCCCM and plated 
into a 75cm2 flask and incubated at 37°C in a humidified atmosphere of 95% air and 
5% CO2.   
 
For further expanding and processing, the floating neurospheres were collected from 
the 75cm2 flask and centrifuged at 1200rpm for 5 minutes. A total of 6ml of the 
supernatant was removed and freshly prepared 6ml NSCCCM was added to resuspend 
the pellet. The cells were plated into the 75cm2 flask and incubated at 37°C in a 
humidified atmosphere of 95% air and 5% CO2. 
 
2.2.2 Primary culture of bone marrow stem cells (BMSC)   
Materials: 
BMSC Maintaining Culture Medium （BMSCMCM）: 
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     DMEM (D1152, Sigma)                                                  390ml 
     Fetal bovine Serum (Hyclone)                                         100ml 
     Antibiotic antimycotic solution (100×) (Sigma)                  5ml 
     200mM L-Glutamine (100x, Gibico)                                   5ml 
 
0.5% trypsin-EDTA solution (Sigma)                                 
 
Sterile PBS (pH7.4) (NUMI, Singapore)             
 
Mouse BMSCs were isolated from 8-week old adult mice. Briefly, the whole bone 
marrow plugs were obtained by flushing the bone marrow cavity of the femurs and 
tibiae of 8-weeks adult Swiss mouse with a 21-gauge syringe filled with DMEM 
supplemented with 20% fetal bovine serum (FBS), 2mM L-glutamine and 100U/ml 
penicillin, 100µg/ml streptomycin and 0.25µg/ml amphotericin B. Cells were passed 
through 70μm cell strainer to remove remaining clumps of tissue, then plated in a 
75cm2 flask and incubated at 37°C in a humidified atmosphere of 95% air and 5% 
CO2. The first medium change was done within 24 hours to remove the non-adherent 
hematopoietic lineage cells, and the adherent cells were continuously grown to 90% 
confluence. 
 
For further expanding and processing, BMSCs were washed twice with 5ml of sterile 
PBS (pH 7.4) and incubated with 6ml of 0.25% trypsin/1mM EDTA for 5 minutes at 
37°C. The reaction was stopped by adding 6ml of BMSCMCM. The detached cell 
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solution was transferred to a sterile Falcon tube and centrifuged at 1200g for 5 
minutes. The supernatant was removed and the cell pellet was resuspended in 12ml of 
maintained culture medium in 75cm2 flasks for passage or was processed for other 
experiments. 
 
2.3 Differentiation of NSCs and BMSCs 
Materials: 
NSC Differentiation Medium (NSCDM) 
     DMEM/F12 (130565, Invitrogen)                                                      9.6ml 
     ITS (100x, Invitrogen)                                                                       0.1ml 
     FBS (Hyclone)                                                                                   0.2ml 
     Antibiotic antimycotic solution (100x, Sigma)                                 0.1ml 
 
BMSC Differentiation Medium (BMSCDM) 
     DMEM (D1152, Sigma) 
     30mM Retinoic acid (RA) (Sigma) 
     FBS (Hyclone) 
     200mM L-glutamine (100x, Invitrogen) 
     Antibiotic antimycotic solution (100x, Sigma) 
 
Poly-ornithine coated coverslips 
Prepare poly-ornithine (MW of 30,000 - 70,000, Sigma) at 0.1-1 mg/ml in 0.15 M 
borate buffer (pH 8.3).  Filters sterilize and stored at -4°C until use. One day before 
the experiment, the autoclaved glass coverslips were soaked in the solution and 
incubated for 24 hours at room temperature.  The poly-ornithine solution were 
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The NSCs were collected from the 75cm2 flask and centrifuged at 1200rpm for 5 
minutes. The NSCCCM was removed and the pellet was resuspended in either 
NSCCCM or NSC differentiation medium. For immunohistochemistry or real-time 
PCR, the NSCs in the NSCDM were seeded into a 6-well plate onto a poly-ornithine 
coated coverslip and were allowed to differentiate for 4 days. The NSCs in the 
NSCCCM were also seeded into a 6-well plate onto poly-ornithine coated coverslips 
and allowed to be seeded down for 2 hours before proceeding to 
immunohistochemistry or the RNA extraction.   
 
BMSCs differentiation 
The BMSCs from the 75cm2 were trypsinized as described before. The reaction was 
stopped by the addition of the same volume of BMSCMCM. After centrifuging at 
1200rpm for 5 minutes, the cell pellet was resuspended in the BMSCMCM and 
seeded onto uncoated glass coverslip in the 6-well plate. The cells were cultured in 
the BMSCMCM for 24 hours and then the BMSCMCM was changed into the 







2.4 Real-time PCR of Bcl-2 family members 
2.4.1 RNA isolation 
After differentiation, the NSCs or BMSCs were washed with PBS for 2 times and 
total RNA was isolated from one well of a 6-well plate using the RNeasy Mini kit 
according to the manufacturer’s protocol. Briefly, after being washed with PBS for 
two times, the cells were lysed in 350μl of Buffer RLT (provided with the kit, 
containing a highly denaturing guanidinium isothiocyanate which immediately 
inactivates RNase) in the 6-well plate. After the lysate was passed through a 22G 
needle for ten times, 350µl of 70% ethanol was then added to the cleared lysate. The 
sample was mixed well to provide appropriate binding conditions, then applied to an 
RNeasy mini spin column (silica-gel membrane, maximum binding capacity is 100µg 
of RNA longer than 200 bases), and spun for 15 seconds at 10,000g. The flow through 
was discarded. During this step, the total RNA binds to the membrane. The RNA 
bound to the membrane was washed with buffer RW1 and RPE (supplied in the kit) 
sequentially. High-quality RNA was then eluted in 30µl of RNase free water. The 
concentration and purity of the extracted RNA were evaluated by spectrophotometric 
absorbance readings at 260nm and 280nm (Eppendorf Biophotometer, USA). 
 
2.4.2 First-strand cDNA synthesis using total RNA as template 
Please refer to page 61 for details. 
 
2.4.3 Real-Time PCR 




2.5 PCR of Diva ORF  
The PCR reaction was employed to investigate if Diva is expressed in the NSC or 
BMSC. The sequences of the primers used for PCR are shown in Table 2. In a sterile 
thin walled PCR tube, 2.5μl Mg2+free 10x buffer, 1.5μl Mg2+ buffer, 0.25μl Taq 
polymerase (Promega, USA), 0.5μl 10mM dNTP, 1μl 5mM FW primer, 1μl 5mM RV 
primer, 1μl cDNA  template, 17.25μl H2O were added in order and mixed well. The 
PCR cycle condition was setup as follows:  
          First denature:                                                     94°C for 2 minutes 
          Then programmed amplification cycle:              94°C for 30 seconds,  
                                                                                      60°C for 30 seconds 
                                                                                      72°C for 1 minute 
                                                                                      45 cycles 
          End with an extension:                                       72°C for 5 minutes   
The specificity and size of the PCR product were examined by electrophoresis 
running on 1.5% agarose gel.  
2.6 Fluorescent double-labelling of Diva with nervous system cell markers  
Double labelling of Diva with some specific cell markers was performed to 
investigate the expression of Diva during the stem cell differentiation. The antibodies 
and concentrations used in the present study are list in Table 7. 
Table 7. Antibodies used for fluorencent immunocytochemistry 
Markers Cell Type Concentraion 
Rabbit anti-NFH (Chemicon, USA) Neurons 1:200 
Rabbit anti-Nestin (Covance, USA) Neural Stem cells 1:200 
Mouse anti-O4 (Chemicon, USA) Oligodendrocytes 1:200 
Rabbit anti-GFAP (Dako, Denmark) astrocytes 1:200 
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The NSCs or BMSCs on the coverslip from 6-well plate were first washed with PBS 
for 5 minutes and incubated with 4% PF for 30 minutes. After two washes by PBS-
TX, the cells were rinsed in PBS-TX for 10 minutes. Cells were then blocked by 5% 
normal rabbit for 1h, and subsequently incubated with the anti-Diva antibody (1:50, 
Santa Cruz, USA) at 4°C overnight. After incubation with the primary antibody, the 
cells were washed 3 times with 1% PBS-TX for about 15 minutes. They were 
incubated for 1 hour in biotinylated rabbit anti-goat secondary antibodies (1:250, 
Vector Lab., USA). The cells were washed with PBS-TX buffer, and incubated with 
Avidin-FITC (1:300, Vector Lab., USA) for 30 minutes. After washing with PBS-TX 
for 3x10 minutes, the slides with cells were blocked with 5% of normal serum in 
PBS-TX for 1 hour and then incubated with antibody of specific cell marker at 4°C 
overnight. The next day, the cells were first washed with PBS-TX 3 x 5 minutes and 
incubated with cy3 or rhodamine conjugated secondary antibody for 1 hour. After 
washing with PBS-TX for 3 x 5 minutes, the coverslips were mounted using 
fluorescent mounting medium containing DAPI (Vector, UK). All the fluorescent 




3.1 PCR of Diva by using NSCs and BMSCs cDNA as template 
PCR experiment was employed to further confirm the expression of Diva in NSCs 
and BMSCs in vitro. The cDNA synthesized from the total RNA from NSC or BMSC 
was used as the template. By using specific primers for the Diva ORF, A specific 
band around 580bps can be seen which is similar to the size of Diva ORF. The results 
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Figure 34. Electrophoresis of Diva ORF  
Diva ORF were cloned by PCR from NSCs or BMSCs. The products were examined in 
1.5% agarose gel by electrophoresis. Electrophoresis shows that a band responding to 
580bp can be seen in both NSCs (A) and BMSCs (B).  
 
3.2 Real-time PCR of Diva during the differentiation of NSCs and BMSCs 
The NSCs were allowed to differentiate in the NSCDM for 4 days and the BMSCs 
were allowed to differentiate in BMSCDM for 10 days. The total RNA was extracted 
and real-time PCR of Diva was carried. The un-differentiated NSCs in NSCCCM and 
BMSCs in BMSCMCM served as control respectively. In both NSCs (A) and BMSCs 
(B) (Fig. 35), the expressions of Diva were dramatically down-regulated. In the NSCs, 
the expression of Diva down-regulated for 55 times compared to that of the un-





Figure 35. Real-time PCR of Diva in NSCs and BMSCs during diffentiation 
The expressions of Diva in the NSC or BMSC before and after differentiation were 
investigated by real-time PCR. In both the NSCs (A) and BMSCs (B), the 
expressions of Diva are dramatically down-regulated in comparison to that of un-
differentiated controls.  
 
3.3 Real-time PCR of other Bcl-2 family members during the differentiation of 
NSCs and BMSCs 
The expressions of other members in the Bcl-2 family members were also 
investigated by the real-time PCR during the NSC or BMSC differentiation. During 
NSC differentiation, some Bcl-2 family members showed down-regulation which 
included BimL, Bak and Bcl-6. One of Bcl-2 family members, Blk, showed an 
increased expression (Fig 36A). During the BMSC differentiation, Mcl-1, Bad, and 
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Bok showed decreased expressions but Bcl-2, Bak and Bcl-xL showed increased 
expressions compared to that of the un-differentiated control (Fig. 36B).  
A 
B 
Figure 36. Real-time PCR of Bcl-2 family members in NSCs and BMSCs 
during diffentiation 
The expressions of Bcl-2 family members in the NSCs or BMSCs before and after 
differentiation were investigated by real-time PCR. During the NSC differentiation (A), 
Blk shows an increase of expression but BimL, Bak and Bcl-xL show decreased 
expressions. During the BMSC (B) differentiation, Mcl-1, Bad and Bok show  decreased 




3.4 Fluorescent double-labelling of Diva with specific cell markers in NSCs 
during differentiation. 
Double labeling of Diva with various cell specific markers including GFAP, NFH, O4 
and Nestin were performed in the NSC during the differentiation. Previous studies 
showed that NSCs were able to differentiate into astrocytes, oligodendrocytes and 
neurons. From the double-labelling experiment, it was noted that Diva showed a much 
higher intensity in un-differentiated NSC than in differentiated NSC (Fig 37, Fig 38, 
Fig 39and Fig 40). The intensity of GFAP immunoreactivity increased in the 
differentiated NSCs compared with that in the un-differentiated ones (Fig. 37). 
However, for the NFH and O4, the immuno-reactivities did not show much difference 
between the differentiated and undifferentiated ones (Fig. 38 & Fig. 39). Nestin has 
now been widely accepted as the neural stem cell marker. Figure 40 shows that the 
intensity of nestin decreased obviously after the differentiation.  
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Figure 37. Double labeling of Diva and GFAP in NSC during differentiation 
GFAP, the marker for astrocyte, is visualized by cy3 (red). Diva is labeled by FITC 
(green). Nuclei are stained by DAPI (blue). In the un-differentiated NSCs (A, B, C), the 
intensity of Diva is much higher than in the differentiated NSCs (D, E, F), indicating a 
downregulation of Diva after differentiation. Howevere, the GFAP expression is 











Figure 38. Double labeling of Diva and NFH in NSC during differentiation 
NFH, the marker for neurons, is visualized by cy3 (red). Diva is labeled by FITC (green). 
Nuclei are stained by DAPI (blue). In the un-differentiated NSCs (A, B, C), the intensity of 
Diva is much higher than that in the differentiated NSCs (D, E, F), indicating a down-
regulation of Diva after differentiation. However, the intensity of NFH does not show 









Figure 39. Double labeling of Diva and O4 in NSC during differentiation  
O4, the marker for oligodendrocyte, is visualized by cy3 (red). Diva is labeled by FITC 
(green). Nuclei are stained by DAPI (blue). In the un-differentiated NSCs (A, B, C), the 
intensity of Diva is much higher than that in the differentiated NSCs (D, E, F), indicating 
a down-regulation of Diva after differentiation. However, the intensity of O4 does not 











Figure 40. Double labeling of Diva and Nestin in NSC during differentiation  
Nestin, the marker for undifferentiated NSC, is visualized by cy3 (red). Diva is labeled by 
FITC (green). Nuclei are stained by DAPI (blue). In the un-differentiated NSCs (A, B, C), 
the intensity of Diva is much higher than that in the differentiated NSCs (D, E, F), 
indicating a down-regulation of Diva after differentiation. Furthermore, the intensity of 
Nestin in un-differentiated NSC is intensive than that in the differentiated NSC as well. 




In this chapter, the expression of Diva in NSCs and BMSCs and the alteration in its 
expression during the differentiation of NSCs and BMSCs were investigated. By PCR, 
we observed that Diva’s mRNA is expressed in both NSCs and BMSCs. By real-time 
PCR, the expression of Diva decreased dramatically after NSCs and BMSCs 
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differentiated. The expressions of other Bcl-2 family members were also investigated 
in both NSCs and BMSCs before and after the differentiation. Interestingly, in these 
two kinds of stem cells, only Diva showed the coincident down-regulation after 
differentiation. The other Bcl-2 family members either showed increased or decreased 
expression. This may indicate that Diva might play an important role in the regulation 
of the cell cycle of stem cells. In consideration of anti-apoptotic role of Diva, it may 
suggest that the differentiated stem cells might become more vulnerable to microglial 
cytotoxicity but further experiments are required to confirm this.  
 
4.1. Diva is expressed in both NSCs and BMSCs in vitro 
Although the Diva protein has been confirmed to be expressed in stem cells in vitro, 
the expression of Diva in NSCs has not been detected in vivo in results of the present 
study. Other studies have indicated that the ependymal cells in the subventricular zone 
in the adult mouse were adult neural stem cells (Johansson et al., 1999). However, 
DAB immunostaining in adult mice did not show any positive staining of Diva in the 
subventricular zone. The Diva expression in the NSCs may be inducible due to the 
change of microenvironment from in vivo to in vitro. 
 
The results further showed that Diva was expressed not only in NSCs but also in 
BMSCs in vitro. In the present study, NSCs were cultured as floating neurospheres in 
the presence of epidermal growth factor (EGF) and hormonal supplement (B27) from 
embryonic murine forebrain. However, the BMSC were cultured in the presence of 
serum only as monolayer cells. This difference may challenge the possibility that 
mitogen (EGF), hormonal factors (B27) or deprivation of serum could induce the 
expression of Diva in the stem cells in vitro. Theoretically, a true NSC should be 
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capable of infinite or extensive self-renewal. However, previous studies have 
indicated that the neurospheres cultured from the SVZ adjacent to the lateral ventricle 
during development could extensively self-renew but the cells propagated from the 
postnatal brains have a more limited capacity for self-renewal (Seaberg et al., 2005). 
This may also explain why Diva is expressed in the NSC cultured from E14.5 embryo 
but do not expressed in the SVZ in adult mouse brain. However, the reasons for why 
Diva is expressed in NSCs and BMSCs in vitro still need to be further clarified.  
 
4.2. Expression of Diva decreased dramatically after differention of the NSCs 
and BMSCs 
Nestin was firstly discovered in the neuroepithelial cells in the neural tube and now 
have been widely accepted as the marker for the NSCs which have the ability to 
generate glia and neurons (Dahlstrand et al., 1992;Lendahl et al., 1990). The 
decreased intensity in nestin immunoreactivity in the present study after the 
differentiation may serve as the indication for NSC differentiation. NSC have been 
reported to be able to differentiate into astrocytes, oligodendrocytes and neurons 
(Reynolds et al., 1992). In this study, after differentiation, the staining intensity of 
astrocyte marker, GFAP, increased obviously. However, the staining intensity of 
oligodendrocyte marker, O4, and the neuronal marker, NFH, did not show very 
obvious difference between differentiated and undifferentiated cells. This may 
indicate that under the current differentiation conditions, the NSCs prefer to 
differentiate into astrocyte-like cells but not oligodendrocyte- and neuron-like cells. 
Importantly, the fluorescence immunostaining has shown that Diva is strongly 
expressed in un-differentiated NSCs and the immunostaining intensity significantly 
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diminished in differentiated NSCs, suggesting that the expression of the Diva protein 
was down-regulated in differentiated NSCs. 
 
4.3. Possible roles of Diva in stem cells 
The down-regulation in expression of Diva has been shown by real-time PCR in 
mRNA level in both NSCs and BMSCs and by immunohistochemistry in protein level 
in NSCs. In previous results of the present study, Diva has been shown not only to 
possess the anti-apoptotic function but also to promote proliferation, indicating that 
Diva may be involved in the cell cycle regulation. Diva is a member of Bcl-2 family 
and structurally similar to the anti-apoptotic members such as Bcl-2, Bcl-xL and Mcl-
1. Bcl-2 has been indicated to be involved in the cell cycle regulation by retarding the 
entry to cell cycle (Winter et al., 1998). Another anti-apoptotic members, Mcl-1, has 
also been indicated to be involved in the cell cycle regulation in which overexpression 
of Mcl-1 significantly inhibited the cell cycle progression through the S-phase (Fujise 
et al., 2000). On the other hand, pro-apoptotic member Bax could promote the cell 
cycle entry (Brady et al., 1996). Classic view about the function of Bcl-2 family 
members in the cell cycle regulation is that anti-apoptotic members could inhibit cell 
proliferation but pro-apoptotic members promote cell proliferation. However, in the 
present study, Diva was shown to be an anti-apoptotic member, but its expression was 
dramatically down-regulated after the cell lost its proliferation ability. The possible 
explanation for this contradiction with previous studies is that Diva could be a 
specific member of Bcl-2 family which may possess the anti-apoptotic function but 
could promote cell proliferation. Therefore, the possible functions of Diva are 
reasonable for stem cell to maintain its “stem status” which requires stronger 
resistibility to environmental stress and remains ability of infinite proliferation for 
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propagation. The results therefore shed more light on some fundamental aspects of 
stem cell research: To study possible involvement of Diva gene in stem cell  






























1. Microglial dual function are related to the equilibrium of factors released 
from activated microglia 
Microglial dual functions have been identified by previous studies, but it is still a 
mystery when and how microglia would exert its neuroprotective/neurotrophic or 
neurodestructive/neurotoxic function. In the present study, microglial dual functions 
were related to the concentration of 1μg/ml LPS stimulated BV-2 microglial condition 
medium (LPS-BVCM). Lower concentrations of the LPS-BVCM in the DMEM/F12 
showed protective effects on the NSC-34 neurons by promoting cell proliferation, 
facilitating outgrowth of cell processes as well as preventing the formation of 
aggregates induced by 2,5-HD. However, higher concentrations of the LPS-BVCM 
could induce apoptosis and suppress the outgrowth of cell processes. In many injury 
and disease models, activation of microglia under constant stimulation has been 
observed gradually becoming more intensive. Similar time-dependant increase has 
been noted in expressions of many cytokines from activated microglia. Furthermore, 
the increase in the number of activated microglia in the disease foci may result in 
increases in both the concentrations of factors released from activated microglia and 
result in a concentration gradient from the diseased or impaired foci to the peripheral 
areas. Combined with these findings, it is reasonable to suggest that the microglial 
functional alteration in vivo may occur according to the degree of microglial 
activation and the spatial distribution of activated microglia in the diseased foci. This 
concept of microglial dual functions has been schematically drawn in figure 41.  In 
this part of the study, by relating the microglia dual functions with the concentrations 
of LPS-BVCM but not one or more specific factors secreted by activated microglia, 
the limitation of previous studies that ignore the network and synergic effects of 
thousands of factors secreted by microglia upon stimulation has been excluded.  
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Figure 41. Schematic drawing of the concept of time and spatial development 
of microglial activation in association with their dual functions  
The black dots indicate either the amount of microglial factors (concentration) or the 
number of activated microglia in/around the diseased or injured region in the CNS. At an 
earlier stage of microglial activation, the number of activated microglia and the amount 
of microglial factors are at a relatively lower range and therefore activated microglia 
may contribute to create a protective/trophic environment for damaged neurons. At a later 
stage, the number of activated microglia increase significantly in the center region 
accompanied with a significant increase in the amount of microglial factors and form a 
concentration gradient from the center to periphery of the disease foci. While destruction 
and clearance are taking place in the center of the disease foci, activated microglia may 
contribute to protect neurons in the vicinity of the diseased foci so as to limit the 
expansion of the damage. 
 
 
2. Diva, one of the Bcl-2 family members, plays a role in protection of NSC-34 
neurons from activated microglial cytotoxicity and can promote cell proliferation 
Bcl-2 family members have been indicated to be involved in the regulation of 
apoptosis and cell cycle entry. After it has been observed that lower concentrations of 
the LPS-BVCM could promote proliferation of NSC-34 neurons but high 
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concentrations of the LPS-BVCM could induce apoptosis of NSC-34 neurons, the 
expressions of Bcl-2 family members during microglial dual effects were further 
investigated. One interesting finding is that, among Bcl-2 family members, only Diva 
expression increased under the protective role of the LPS-BVCM. By overexpression 
of Diva in the NSC-34 cells, it was found that Diva not only possessed an anti-
apoptotic role, but could also promote proliferation of NSC-34 cells. This is 
interesting because most of the previous studies have indicated that anti-apoptotic 
Bcl-2 family members were able to inhibit the cell cycle entry but pro-apoptotic Bcl-2 
family members promote the cell proliferation. Diva is structurally similar to anti-
apoptotic members of Bcl-2 family such as Bcl-2 and Mcl-1. The function of Diva 
during apoptosis has been confirmed to be anti-apoptotic, which is coincident with 
previous studies that BH domain played an important role during the apoptosis. 
However, promoting cells to enter the cell cycle by an anti-apoptotic Bcl-2 family 
member has never been reported before.  
 
3. Diva is expressed in specific neurons in CNS 
The distribution of Diva in vivo was also investigated. Contradictory to previous 
studies, Diva was found to be expressed in the CNS including the mid-brian, pons, 
medulla oblongata,  and spinal cord. More interestingly, by DAB 
immunohistochemical and double fluorescence labelling, Diva-positive cells were 
only limited to neurons in a few specific nuclei in the brain stem and in the ventral 
horn of the spinal cord. Furthermore, it now has been widely accepted that 
neurospheres can be virtually present in any region of the CNS that contains a 
germinal center from adult mouse but with limited self-renewal ability compared with 
the stem cells from the embryo. So the current results may point out a new cell 
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population in the CNS that neurospheres propagated from them may have less or no 
limitation of self-renewal ability. The regulation of Diva during the NSC cell cycle 
may also provide a new way to manipulate the fate of neural stem cells.  
 
4. Dramatic down-regulation of Diva’s expression after the stem cell 
differentiation indicates that Diva may possilbly be involved in the regulation of 
cell cycle in stem cells. 
Other than the above,  Diva expression during the differentiation of stem cells was 
also investigated. The dramatic down-regulation of Diva after the differentiation of 
NSCs and BMSCs were detected by the real-time PCR. Among the Bcl-2 family 
members, only Diva showed a constant dramatic down-regulation during 
differentiation of both stem cells. After differentiation, the self-renewal ability of stem 
cells may also become limited indicating that Diva may be involved in the cell cycle 
regulation and most probably promoting/maintaining the cells in the cell cycle. In 
consideration of anti-apoptotic role of Diva, this protein may play an important role in 
stem cell homing in the CNS, where the stem cells would face challenges from 
various cells, especially microglia, the immune cells of the CNS. 
 
5. Future work 
The current research started from microglial dual effects, focused on the roles of Bcl-
2 family members in neurons which was facing the microglial dual effects, and finally 
ended at creating a possible research direction to study possible involvement of Diva 
in controlling of stem cell proliferation and differentiation and  possible role in 
survival of stem cells after transplantation in facing microglial dual effects.  
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In cell therapy strategy for treatment of neurodegenerative diseases and nerve injuries, 
Diva may come to the center stage of future studies. First, the function of Diva should 
be further studied in details in knock-down as well as overexpression models. 
Secondly, the identification of Diva interacting proteins in the stem cells should be 
focused. Lastly, the upstream and downstream signaling components of Diva 
expression should be studied. The alterations in these components should be 
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